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Abstract 
Tankyrases belong to the Diphtheria toxin-like ADP-ribosyltransferase (ARTD) 
enzyme superfamily, also known as poly(ADP-ribose) polymerases (PARPs). 
They catalyze a covalent post-translational modification reaction where they 
transfer ADP-ribose units from NAD+ to target proteins. Tankyrases are involved 
in many cellular processes and their roles in telomere homeostasis, Wnt signaling 
and in several diseases including cancers have made them interesting drug 
targets. In this thesis project, selective inhibition of human tankyrases was 
studied.  
A homogeneous fluorescence-based assay was developed to screen the 
compound libraries. The assay is inexpensive, operationally easy, and performs 
well according to the statistical analysis. Assay suitability was confirmed by 
screening a natural product library. Flavone was identified as the most potent 
inhibitor in the library and this motivated us to screen a larger flavonoid library. 
Results showed that flavones were indeed the best inhibitor of tankyrases among 
flavonoids. To further study the structure-activity relationship, a small library of 
flavones containing single substitution was screened and potency measurements 
allowed us to generate structure-activity relationship. Compounds containing 
substitutions at 4´-position were more potent in comparison to other 
substitutions, and importantly, hydrophobic groups improved isoenzyme 
selectivity as well as the potency. A flavone derivative containing a hydrophobic 
isopropyl group (compound 22), displayed 6 nM potency against TNKS1, 
excellent isoenzyme selectivity and Wnt signaling inhibition. Protein interactions 
with compounds were studied by solving complex crystal structures of the 
compounds with TNKS2 catalytic domain. A novel tankyrase inhibitor (IWR-1) 
was also crystallized in complex with TNKS2 catalytic domain. The crystal 
structure of TNKS2 in complex with IWR-1 showed that the compound binds to 
adenosine site and it was the first known ARTD inhibitor of this kind.  
To date, there is no structural information available about the substrate binding 
with any of the ARTD family members; therefore NAD+ was soaked with 
TNKS2 catalytic domain crystals. However, analysis of crystal structure showed 
that NAD+ was hydrolyzed to nicotinamide. Also, a co-crystal structure of NAD+ 
mimic compound, EB-47, was solved which was used to deduce some insights 
about the substrate interactions with the enzyme.  
 vii 
Like EB-47, other ARTD1 inhibitors were also shown to inhibit tankyrases. It 
indicated that selectivity of the ARTD1 inhibitors should be considered as some 
of the effects in cells could come from tankyrase inhibition. 
In conclusion, the study provides novel information on tankyrase inhibition and 
presents new insight into the selectivity and potency of compounds.  
  
 viii 
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1 Review of the literature 
1.1 Introduction 
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in several 
redox reactions in the living cells (Belenky et al, 2007). NAD+ binds to the 
proteins through special types of protein folds. The most established of them is 
Rossmann fold, which was first found in the nucleotide binding proteins such as 
dehydrogenase (Rossmann et al, 1974). It is a protein structural motif consisting 
of six parallel beta strands linked to two pairs of alpha helices. It binds to NAD+ 
through a pair of Rossmann folds because one fold can bind to only one 
nucleotide moiety. In addition, domain containing Rossmann fold also binds to 
NAD+ of three other known classes of proteins. These include ADP-
ribosyltransferases, ADP ribosyl cyclases and sirtuins (Belenky et al, 2007; 
Koch-Nolte et al, 2009). This thesis focuses on human ADP-ribosyltransferases 
(ARTDs) (EC 2.4.2.30), previously known as poly(ADP-ribosyl) polymerases 
(PARPs). ARTDs were first described in 1960s and since then they have been 
implicated in wide range of cellular processes (Chambon et al, 1963). ARTDs 
catalyze poly(ADP)ribosylation (PARsylation) reaction and modify proteins that 
mediate DNA-damage repair, cell signaling, energy metabolism and gene 
transcription (Hassa & Hottiger, 2008). 
To date, seventeen members of this enzyme superfamily have been identified and 
some of them have been characterized. ARTD family members cleave NAD+ to 
nicotinamide and ADP-ribose, and attach the ADP-ribose moieties onto target 
proteins (heteromodification) or on themselves (automodification) reviewed in 
(Hottiger et al, 2010) (Fig. 1). In order to discover the acceptor sites for ADP-
ribosylations, a mutant of ARTD1 capable of catalyzing only mono-ADP-
ribosylation was used and ribosylated product was separated using HPLC. Mass 
spectrometric analysis of digested ribosylated product with trypsin revealed that 
glutamate and aspartate residues act as acceptor sites for ADP-ribosylation 
reaction (Tao et al, 2009). In another study, chemical linkage stability studies 
utilizing the automodification reaction capacity of PARP1/ARTD1 showed that 
lysines also act as the acceptor sites for ADP-ribosylation (Altmeyer et al, 
2009a).   
It was noticed that some of the family members were not able to catalyze the 
polymerization reaction but function as mono ADP-ribosyl transferases (Kleine 
et al, 2008; Otto et al, 2005). This led to a new proposed nomenclature of PARPs 
as Diphtheria toxin like ADP-ribosyltransferases (ARTDs) (Hottiger et al, 2010). 
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Figure 1. ARTDs hydrolyze the substrate NAD+ and catalyze the covalent modification 
of the acceptor protein by adding the ADP-ribose units onto mainly glutamate, aspartate 
or lysine residues.  Elongation and branching points are also indicated. 
ARTD1/PARP1 and ARTD2/PARP2 are able to synthesize linear or branched 
ADP-ribose polymers and the length of the polymers could reach 200 units in 
vitro and in vivo (Alvarez-Gonzalez & Jacobson, 1987; Juarez-Salinas et al, 
1983, 1982; Kanai et al, 1982; Miwa et al, 1981). Catalytic activity of 
ARTD3/PARP3 and ARTD4/PARP4 is not well-studied. However, ARTD1, 
ARTD2 and ARTD3 interacts with DNA and co-operates with the catalytic 
domain, and their activity is DNA-dependent (Amé et al, 1999; Boehler et al, 
2011; Langelier et al, 2010). Tankyrases (PARP5A/TNKS1/ARTD5 and 
PARP5B/TNKS2/ARTD6) are known to form linear oligomers, only up to an 
approximate length of 20 subunits and no branching has been observed yet 
(Rippmann et al, 2002). ARTD7, ARTD8 and ARTD10 are characterized as 
mono ADP-ribosyltransferases (Kleine et al, 2008; Otto et al, 2005). Polymer 
forming ARTDs contain an amino acid motif HYE in their catalytic core, 
whereas, proposed mono ARTDs have HYI/L/Y motif. ARTD9 and ARTD13 
have QYT and YYV amino acid motifs respectively and likely their catalytic 
domains do not have ADP ribosylation activity (Kleine et al, 2008). Other 
ARTDs have not been studied in detail so far and more efforts are needed to 
characterize them.  
1.1.1 ARTD activation, poly(ADP-ribosyl)ation reaction and ARTD 
catabolism 
The most studied ARTD family member, ARTD1, is activated in response to the 
transient DNA strand breaks caused by various biological processes such as 
DNA replication, recombination, repair, damage and gene arrangement (Hassa & 
Hottiger, 2008). Other processes, which could activate the ARTDs are oxidative 
stress and DNA-binding drugs. Some of the activated ARTDs are capable of 
forming PAR polymers (Chambon et al, 1963). These PAR chains are negatively 
charged and their breakdown is mostly catalyzed by poly(ADP-ribose) 
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glycohydrolases (PARG) and ADP-ribosyl hydrolase-3 (ARH3) (Gagné et al, 
2006; Oka et al, 2006). However, PARGs cannot remove the terminal ADP-
ribose moiety present on the target proteins (Dunstan et al, 2012; Slade et al, 
2011). The breakdown of ADP-ribose from the mono(ADP-ribosylated) proteins 
and also the catalysis of the last remaining ADP-ribose moiety are performed by 
ARH class of enzymes (Oka et al, 2006). Three proteins of the ARH family 
named ARH1-3 are expressed in mammals (Koch-Nolte et al, 2008). ARH1 
function is to remove ADP-ribose moiety from ADP-ribosylated arginine 
residues whereas ARH3 hydrolyses the O-acetyl-ADP-ribose (Ono et al, 2006). 
It has been proposed that ARH3 is involved in the catalysis. Another protein that 
removes mono ADP-ribosylation from PARP modified proteins is terminal ADP-
ribose protein glycohydrolase (TARG) (Sharifi et al, 2013).   
1.2 ARTDs and their functions 
1.2.1 ARTD1 
The best studied and most characterized among ARTDs is ARTD1, which is a 
nuclear protein (Barth et al, 2006). However, a study where ARTD-related 
functions were disrupted by a ARTD antisense vector, suggested that ARTD1 
could also be present in the mitochondria (Druzhyna et al, 2000; Scovassi, 2004). 
Human ARTD1 consists of six functionally distinct domains (Fig. 2, Table 1). 
The domain at the N-terminus is DNA binding domain (DBD) which is 
composed of two zinc fingers Zn1 and Zn2. They are involved in binding to 
DNA breaks by recognizing the DNA structures (D’Silva et al, 1999; Pion et al, 
2003). The Zn3 domain is structurally different from Zn1 and Zn2 and is required 
for ARTD1 interdomain communication and also for condensing chromatin 
(Langelier et al, 2010, 2008); the automodification region (AR) forms the central 
part of the enzyme and comprises of breast cancer susceptibility protein C-
terminus motif (BRCT), which is present in many DNA repair and cell cycle 
proteins (Bork et al, 1997) (Fig. 2, Table 1). 
The AR also contains amino acid residues for the covalent attachment of PAR 
(Altmeyer et al, 2009b; Tao et al, 2009). ARTD1 contains WGR domain at the 
carboxy terminus of AR, which is rich in tryptophan, glycine and arginine. WGR 
is required for the DNA-dependent activity of ARTD1 (Altmeyer et al, 2009b). 
The C-terminal catalytic domain is further divided into two subdomains: the 
regulatory subdomain (RD) and the ADP-ribosyltransferase subdomain (ARTD). 
The ARTD domain catalyzes three different enzymatic reactions: initiation by 
attachment of the first ADP-ribose moiety to the acceptor protein, elongation of 
the chain by addition of ADP-ribose units and generation of the branching points. 
This catalytic domain marks the signature of the ARTD/PARP family and 
contains critical residues for NAD+ binding and catalysis. The Zn1, Zn3, WGR 
and ARTD domains are essential for ARTD1 DNA-dependent activity (Altmeyer 
et al, 2009b; Langelier et al, 2012, 2011, 2008; Tao et al, 2008). Whereas, 
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deletion of Zn2 domain or BRCT motifs did not affect the DNA-dependent 
activity of human ARTD1 (Altmeyer et al, 2009a; Langelier et al, 2011). 
ARTD1 acts as a DNA damage sensor and a signaling molecule binding to both 
single and double-stranded DNA breaks (Langelier et al, 2011). It has complex 
biological functions and is implicated in many cellular processes such as DNA 
repair (Malanga & Althaus, 2005), regulation of replication and differentiation 
(Yang et al, 2004), apoptosis and maintenance of genomic integrity (Koh et al, 
2005), and in the expression of many proteins at transcriptional level (Hassa & 
Hottiger, 2008; Schreiber et al, 2006).        
 
 
Figure 2. Domain organization of human ARTD superfamily members containing 
poly(ADP-ribos)ylation activity. The following domains are indicated; ARTD: catalytic 
ART domain, Zn: Zinc finger motif, BRCT: BRCA 1C Terminus domain, WGR: 
Tryptophan Glycine Arginine rich domain, RD: Regulatory domain, SAP: 
SAF/Acinus/PIAS-DNA-binding domain, D: DNA-binding motif, VIT: Vault protein 
inter-alpha-trypsin domain, vWA: von Willebrand type A, MVP-ID: Major-vault protein 
interaction domain, HPS: Histidine Proline Serine rich region, ARC: Ankyrin repeat 
clusters, SAM: Sterile-α motif.  
1.2.2 ARTD2 
ARTD2 is DNA-dependent nuclear protein (Fig. 2, Table 1). Out of all the 
ARTD members, ARTD2 is the closest relative to the founding member ARTD1 
with 51 % identity in the catalytic ARTD domain. ARTD2 lacks the AR and its 
DNA binding domain (DBD) is different from ARTD1 (Amé et al, 1999; Oliver 
et al, 2004). Like ARTD1, it also contains the WGR and RD domain and has a 
catalytic domain at the carboxy terminus. The DNA binding domain of ARTD2 
(SAP) shows no homology to any other ARTD reported and it may be 
responsible for the different substrate specificity in comparison to ARTD1 (Fig. 
2) (Kutuzov et al, 2013; Oliver et al, 2004). The N-terminus also contains a 
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nuclear localization signal. The main role of ARTD2 is the same as of ARTD1 as 
it acts as a sensor and signaling molecule in response to DNA damage. ARTD2 
has other proposed functions in genome integrity, spermatogenesis, adipogenesis 
and T cell development (Yélamos et al, 2008).  
1.2.3 ARTD3 
ARTD3 also contains a WGR domain as well as a catalytic domain (Fig. 2, 
Table 1). Some earlier studies have shown that unlike ARTD1 and ARTD2, 
ARTD3 is only moderately activated by DNA (Boehler et al, 2011). The main 
functions of ARTD3 are not well understood. However, it is thought to contribute 
to the cell division check point connecting the mitotic fidelity to the DNA 
damage (Augustin et al, 2003; Boehler et al, 2011).     
Table 1. Human ARTD superfamily members and their characteristics. Molecular 
weights and amino acid length are indicated for canonical sequences.  
ARTDs Other names Amino 
acids 
MW 
(kDa) 
ADP-ribosylation 
activity 
ARTD1 PARP1 1014 113 Poly 
ARTD2 PARP2 583 66 Poly 
ARTD3 PARP3 533 60 Poly 
ARTD4 PARP4 1724 193 Poly 
ARTD5 PARP5a/TNKS1 1327 142 Poly 
ARTD6 PARP5b/TNKS2 1166 123 Poly 
ARTD7 PARP15 656 73 mono* 
ARTD8 PARP14 1801 202 mono* 
ARTD9 PARP9 854 96 inactive 
ARTD10 PARP10 1025 110 mono 
ARTD11 PARP11 331 39 mono* 
ARTD12 PARP12 701 79 mono* 
ARTD13 PARP13 902 101 inactive 
ARTD14 PARP7 657 76 mono* 
ARTD15 PARP16 322 36 mono* 
ARTD16 PARP8 854 96 mono* 
ARTD17 PARP6 630 71 mono* 
ARTD18 TRPT1 253 28 mono* 
*postulated activity 
 
1.2.4 ARTD4 
ARTD4 is located in the cytoplasmic vaults and is a component of the vault 
complex, a large cytoplasmic ribonucleoprotein (RNP) assembly (Kickhoefer et 
al, 1999). ARTD4 is larger in comparison to other known ARTD members (Fig. 
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2, Table 1). It comprises of five major domains, which are breast cancer 
susceptibility protein C terminus (BRCT) motif, catalytic ARTD domain, the 
vault protein inter-α-trypsin (VIT) domain, von Willebrand type A (vWA) and 
finally the major vault protein particle interacting domain (MVP-ID). BRCT 
domain is thought to bind phosphorylated DNA damage-sensing proteins (Manke 
et al, 2003). VIT and vWA domains are presumed to mediate protein-protein 
interactions, reviewed in (Hassa & Hottiger, 2008). It should be noted that ARTD 
domain is located close to the N-terminus in comparison to C-terminal in other 
ARTDs. MVP-ID as the name suggests interacts with the major vault protein. 
MVP mRNA levels are shown to be an indicator of the multi drug resistance 
(MDR), which is a major cause of chemotherapy failure in the cancer patients 
(Laurençot et al, 1997; Siva et al, 2001; Wittes & Goldin, 1986). ARTD4 is also 
present in the nucleus where it is not attached to the vault components 
(Kickhoefer et al, 1999). ARTD4 is loosely bound to the vault protein particle 
and it might have some other functions also. DNA damage does not activate 
ARTD4 and its biological roles are unknown so far.         
1.2.5 Mono (ADP-ribosyl) transferases 
As mentioned earlier, mono ADP-ribosyltransferases have amino acid 
substitutions in their catalytic centers and that enables them to attach just mono 
ADP-ribose moieties to the target proteins (Hottiger et al, 2010; Kleine et al, 
2008). This subfamily comprises of ARTD7-ARTD17 excluding ARTD9 and 
ARTD13 which are described as inactive or pseudo ARTDs (Table 1). 
Mono(ADP-ribosyl) transferases do not contain the catalytic glutamate present in 
polymer forming ARTDs (HYE), which is required for elongation of the ADP-
ribose chain (Otto et al, 2005). They are proposed to utilize the glutamate of the 
substrate protein and thus follow the substrate-assisted catalysis mechanism 
(Kleine et al, 2008). It has been indicated in several studies that mono ADP-
ribosyltransferases play critical roles in intracellular signaling, transcription, 
immunity, inflammation, and stress response (Feijs et al, 2013).     
1.3 Tankyrases 
Tankyrases (TNKSs) are able to catalyze PARsylation reaction along with other 
PAR forming members (ARTD1-ARTD4). This subfamily contains two 
members, one is known as TNKS1 but also referred to as ARTD5 or PARP5a, 
likewise second member TNKS2 is also known as ARTD6 or PARP5b (Fig. 2, 
Table 1). Tankyrases are located in the cytoplasm and are more concentrated 
near the nuclear envelope and Golgi apparatus (Chi & Lodish, 2000; Smith et al, 
1998). Tankyrases were first identified as the components of the human telomeric 
complex, known as shelterin complex (Smith et al, 1998). Tankyrases differ from 
other ARTD members because of their unique domain organization (Fig. 2).  
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TNKS1 and TNKS2 are very similar to each other in their domain construction. 
They contain a SAM domain (sterile alpha motif) which is required for the 
TNKS oligomerization and the characteristic catalytic ARTD domain that 
synthesizes the poly(ADP-ribose) units onto the acceptor proteins and to itself. 
The N-terminal consists of a region comprising of 24 ankyrin repeats, which are 
segmented into five ankyrin repeat clusters (ARC I-V). Ankyrin repeat clusters 
(ARCs) interact with the target proteins and their phylogenetic analysis showed 
that ARC III is less conserved in comparison to other ARCs (Seimiya et al, 
2004). In another study, solution-based library screen was used and binding of 
tankyrase substrate c-Abl Src homology 3 domain-binding protein-2 (3BP2) with 
ARCs was studied. It was found that all the ARCs except ARC III were able to 
bind to 3BP2. Sequence alignment analysis of ARCs showed that ARC III lacks 
the conserved region that corresponds to the peptide-binding pockets (Guettler et 
al, 2011).  
TNKS1 has an additional region at the N-terminal that contains the homo 
polymeric runs of histidine, proline and serine, thus named as HPS region. This 
additional region most likely has a regulatory function, although it is not well 
studied and its main function is unknown so far. The overall sequence identity 
between TNKS1 and TNKS2 is 82 % and sequence identity of the catalytic 
ARTD domain is 89 %. Unlike other polymerases, tankyrases do not contain an 
α-helical regulatory domain, which is required for the catalytic activity of 
ARTD1 in response to DNA damage.  
1.3.1 Crystal Structure 
The crystal structures of the catalytic domain of both the tankyrases have been 
solved, but complete structural information of the full-length tankyrases is not 
available so far. The catalytic ARTD domains of tankyrases have the same α/β 
fold as present in other ARTDs. They also contain a unique zinc binding region 
with an unknown function (Fig. 3) (Karlberg et al, 2010; Lehtiö et al, 2008). The 
tankyrase catalytic domain contains a characteristic ARTD signature motif (β-α-
loop-β-α) (Bell & Eisenberg, 1997) as present in other ARTDs (Fig. 3). 
Tankyrases lack a 32-residue loop on the back side of ARTD domain, which is 
present in ARTD1 (Lehtiö et al, 2008). The catalytic ARTD domains of 
tankyrases have two different binding sites for NAD+ and target protein. The 
analysis of crystal structures of ARTD1 and tankyrase ARTD domains have 
established that NAD+ binding site is structurally equivalent among them. 
Furthermore, NAD+ binding cavity can be subdivided into two distinctively 
different sites, one binding to the nicotinamide and other one binding to the 
adenosine moieties. This is where all of the reported inhibitors bind and most of 
the inhibitors actually occupy the nicotinamide-binding site (Fig. 3). The 
interactions shared by inhibitors binding at nicotinamide-binding site are 
discussed further in section 1.6.5.  
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Figure 3. Stereo view of crystal structure of catalytic domain of human TNKS2 in 
complex with IWR-1. Tankyrase monomers are colored from blue at the N-terminus to 
red at the C-terminus. Nicotinamide binding site (NI), zinc atom (purple sphere) and 
secondary structural elements are labeled. The disordered loop is shown as a dashed line.   
Notably, the NAD+ bound crystal structure is not available yet for any of the 
ARTD-family members. As mentioned earlier, tankyrases are missing the 
regulatory domain that makes their NAD+ binding site more exposed to the 
substrate in comparison to ARTD1-ARTD3. The NAD+ binding site in the 
crystal structures of unbound catalytic domain is lined by a short sequence of 
amino acid residues that is commonly known as donor loop (D-loop) and it 
adopts different conformations in many ARTDs. The D-loops of tankyrases are 
identical in sequence but are present in different conformations in the solved 
crystal structures. In ligand free crystal structures of TNKS1 and TNKS2, D-loop 
is found in closed conformation. In case of TNKS1, the D-loop is closed near the 
nicotinamide site mainly by hydrophobic residues (Lehtiö et al, 2008), whereas 
in TNKS2, it is closed at the adenosine site by His1048 (Karlberg et al, 2010). 
However, analysis of co-crystal structures of tankyrases with bulky ligands 
showed that D-loop is flexible and opens up in order to accommodate the 
compounds (Haikarainen et al, 2013b; Narwal et al, 2013b, 2012b).   
1.3.2 Tankyrase modifications 
Tankyrases undergo post-translational modifications, which might be related to 
the regulation of their catalytic activities. TNKS1 is phosphorylated by various 
kinases such as mitogen-activated protein kinase (MAPK) (Chi & Lodish, 2000), 
glycogen synthase kinase 3 (GSK3) (Yeh et al, 2006b) and Polo-like kinase 1 
(PLK1) (Ha et al, 2012). However, the exact molecular effects of these 
phosphorylations are not clear. MAPK modifies TNKS1 during insulin 
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stimulation but it does not appear to affect the glucose transporter type 4 
(GLUT4)-mediated glucose uptake, where TNKS1 plays a role (Chi & Lodish, 
2000). The phosphorylation by GSK3 seems to occur only during mitosis (Yeh et 
al, 2006b). PLK1 mediated phosphorylation appears to stabilize the TNKS1 
levels and also increases its catalytic activity (Ha et al, 2012). Recently, it has 
been demonstrated that TNKS2 exhibits eight sites which are hydroxylated by 
the factor inhibiting hypoxia inducible factor (FIH)-catalyzed post-translational 
hydroxylation (Cockman et al, 2009). The exact functions of these post-
translational modifications are also poorly understood. Auto-PARsylation of 
tankyrases provides a recognition signal that could be utilized for the 
ubiquitination by the WWE domain of the E3 ubiquitin ligase RING finger 
protein 146 (RNF146). Ubiquitination causes the proteasomal degradation of the 
PARsylated proteins (Callow et al, 2011; Zhang et al, 2011).  
1.3.3 The SAM domain  
The SAM domain has been demonstrated to be required for the optimal catalytic 
activity and also for the polymerization of tankyrases to assemble large protein 
complexes (De Rycker & Price, 2004). Auto-PARsylation causes the 
disassembly of oligomeric complexes of proteins. Tankyrases have been 
proposed as scaffolding molecules (Seimiya & Smith, 2002; Seimiya et al, 2004) 
and it is likely that they use SAM domains along with their respective catalytic 
ARTD domains to assemble and disassemble large protein frameworks at 
different locations in the cell (De Rycker & Price, 2004). It has also been shown 
previously that TNKS1 and TNKS2 associate with each other in in vivo  (Sbodio 
et al, 2002). However, it is still need to be confirmed if this binding is established 
through SAM domains.  
1.3.4 The ankyrin repeats and the target specificity  
As mentioned earlier, tankyrases contain 24 ankyrin repeats which are further 
segmented into five ankyrin repeat clusters (ARC I - ARC V) (Fig. 2). These 
ankyrin repeat clusters (ARCs) are involved in the substrate binding via their 
multiple binding sites for the interacting partners. ARCs have potential 
redundancy in their functions as earlier studies have indicated that they, 
individually or in combination, were able to bind to tankyrase binding partners 
(Seimiya & Smith, 2002). ARCs have been shown to interact with a number of 
proteins and it has been established that a consensus binding motif (RXXPXG) is 
required for the binding; where arginine and glycine are at position 1 and 6 
respectively, X denotes any amino acid, and there could be a small hydrophobic 
amino acid at position 4 (De Rycker et al, 2003; Guettler et al, 2011; Seimiya & 
Smith, 2002; Seimiya et al, 2004). Recently, a crystal structure of TNKS2 in 
complex with its Wnt signaling partner axis inhibition protein (Axin) was 
reported that showed that binding of other proteins could promote tankyrase 
dimerization (Morrone et al, 2012). 
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1.4 Functions of tankyrases 
Tankyrases are present in a variety of human tissues and have been implicated in 
several functions. They are expressed in adipose tissue, kidney, thymus, brain, 
endocrine pancrease, skeletal muscle, spleen and are present abundantly in testis 
(Chiang et al, 2008; Yeh et al, 2009). 
Table 2. List of some of the known tankyrase binding proteins 
Protein function(s)  Reference(s) 
Telomere-repeat 
binding factor-1 
(TRF1) 
telomere binder factor and 
negative regulator of 
telomere length 
(Smith et al, 1998) 
AXIN1/2  tumor suppressor protein 
involved in Wnt signaling 
(Huang et al, 2009) 
Insulin-regulated 
aminopeptidase (IRAP) 
insulin signaling pathway (Chi & Lodish, 2000; 
Sbodio & Chi, 2002; 
Sbodio et al, 2002) 
Glucose transporter 
(GLUT4)  
glucose transporter  (Chi & Lodish, 2000), 
Nuclear mitotic 
apparatus protein 
(NuMA)  
spindle pole marker (Chang et al, 2005a, 
2005b; Sbodio & Chi, 
2002) 
182- kDa tankyrase 
binding protein 
(TAB182)  
tankyrase binder with 
unknown function 
(Sbodio & Chi, 2002) 
Myeloid cell leukemia 
1 (Mcl-1) 
regulator apoptosis (Bae et al, 2003) 
Epstein- Barr nuclear 
region (EBNA1)  
maintenance of the viral 
genome  
(Deng et al, 2005, 2002) 
Formin-binding protein 
1 (FNBP1/FBP17) 
nuclear phosphoproteins 
required for limb and 
renal development 
(Fuchs et al, 2003) 
Cancer susceptibility 
candidate 3 (CASC3)  
regulate splicing , 
metabolism, export and 
localization of mRNA 
(Zhang et al, 2011) 
Basic leucine zipper 
nuclear factor 1 
(BLZF1) 
Maintenance of Golgi 
structure and protein 
transport  
(Zhang et al, 2011) 
c-Abl Src homology 3 
domain-binding 
protein-2 (3BP2)  
regulate signaling from 
immunoreceptors 
(Levaot et al, 2011) 
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Table 3. List of some of the proposed tankyrase binding proteins 
 Protein function(s) Reference(s) 
 Growth factor 
receptor-bound 
protein 14 
(GRB14) 
regulate signaling  (Lyons et al, 2001) 
 A homeobox 
protein HOXB2 
transcription factor (Sbodio & Chi, 2002) 
 Polymorphic 
variant of the 
protein 
phosphatase 1 
regulated subunit 
12 C (PP12C) 
regulates myosin 
phosphatase activity 
(Sbodio & Chi, 2002) 
 Tax1-binding 
protein 1 
(TAX1BP1) 
apoptosis regulation (Sbodio & Chi, 2002) 
 Alpha 1S subunit 
of the voltage-
dependent L-type 
calcium channel 
(CACNA 1S) 
regulate excitation-
contraction coupling in 
skeletal muscles 
(Sbodio & Chi, 2002). 
 Ubiquitin-specific 
protease 25 
(USP25) 
involved in cell cycle 
regulation and stress 
response 
(Sbodio & Chi, 2002). 
A diverse range of tankyrase binding proteins are reported and with some of 
them the interactions are well characterized (Table 2). In addition, several 
proteins have been proposed to contain a tankyrase binding motif RXXPXG (De 
Rycker et al, 2003; Guettler et al, 2011; Seimiya & Smith, 2002; Seimiya et al, 
2004). A few of them are listed in Table 3. This indicates that tankyrases have 
many roles in the cell and some of the best-characterized functions of the 
tankyrases will be discussed in detail in the following paragraphs. 
1.4.1 Telomere maintenance 
Telomeres are protective noncoding repetitive nucleotide sequences at the ends 
of the eukaryotic chromatids. They cannot be replicated by the DNA replication 
machinery because of the end replication problem (Counter et al, 1994). As a 
consequence of this, telomeres become shorter after each replication cycle unless 
synthesized by a telomerase enzyme. Telomerase is a reverse transcriptase 
containing its own RNA template and a catalytic subunit. In most of the human 
cells, the activity of the telomerase is repressed.  
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However, it is found to be upregulated in some normal cells and in almost all 
types of cancers (Shay & Bacchetti, 1997). Telomeres consist of TTAGGG 
repeats and are protected by shelterin complex. Shelterin complex is composed of 
telomere repeat factor 1 (TRF1), telomere repeat factor 2 (TRF2), protection of 
telomeres 1 (POT-1), TRF interacting protein 2 (TIN2), tripeptidyl-peptidase 1 
(TPP1), and repressor/activator site-binding protein (rap1) (Fig. 4). In the 
absence of shelterin complex, telomeres would be inappropriately processed by 
DNA damage surveillance machinery. TNKS1 plays a central role at the 
telomeres by binding to TRF1 (Smith et al, 1998).  
 
 
 
Figure 4.  Telomere elongation by TNKS1. Telomeres are protected by Shelterin 
complex consisting of TRF1, TRF2, TPP1, Rap1, Pot1 and TIN2. TNKS1 PARsylates 
TRF1 and removes it from the telomeres, this gives access of telomeres to telomerases. 
Modified TRF1 is further ubiquitinated before undergoing to proteosomal degradation. 
TRF1, which is part of shelterin complex, blocks the access of telomeres to 
telomerases and therefore serves as a negative regulator of the telomere length 
(Palm & de Lange, 2008). Ankyrin repeats of tankyrases contain a TRF1 binding 
site in ARC V subdomain (Seimiya et al, 2004). The catalytic ARTD domain 
PARsylates TRF1 (Smith et al, 1998) and adds negative charge to TRF1, 
reducing its ability to bind telomeres. Consequently, the telomeres become 
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accessible to telomerases, while released TRF1 is ubiquitinated and subjected to 
proteasomal degradation (Fig. 4) (Her & Chung, 2009; Lee et al, 2006). 
Consistent with these observations, it has also been shown that telomere 
elongation and shortening could be induced by the overexpression and 
suppression of TNKS1, respectively (Cook et al, 2002; Donigian & de Lange, 
2007; Seimiya et al, 2005; Smith & de Lange, 2000). Long telomeres are typical 
in cancer cells and inhibition of telomerase has been proposed as a potential 
therapeutic strategy (Seimiya et al, 2005). Moreover, inhibition of the human 
tankyrases by non-specific inhibitors such as 3-aminobenzamide (3-AB) and PJ-
34 enhance telomere shortening (Seimiya, 2006). Therefore, a combinatorial 
approach to inhibit telomerases and tankyrase might be beneficial in the cancer 
therapy. 
1.4.2 Role in Wnt signaling pathway 
Wnt signaling pathway plays essential roles in embryonic development, cell fate 
specification, stem cell regeneration, neuronal migration and in the adult tissue 
homeostasis (MacDonald et al, 2009). Wnt proteins are signaling molecules that 
are involved in the cell-to-cell interactions during embryogenesis.  
 
 
 
Figure 5. Role of TNKSs in Wnt signaling. In the absence of Wnt ligand, β –catenin 
destruction complex (BCDC) remains intact and causes the degradation of β-catenin. 
Whereas in the presence of a Wnt ligand, BCDC members dissociate and leads to the 
stabilization of β-catenin and finally activation of the target genes. TNKSs modifies 
AXIN and causes the stabilization of β-catenin.    
Inappropriate activation of Wnt signaling pathway has been implicated in many 
cancers (Polakis, 2007, 2000). A striking feature of the Wnt pathway is its 
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involvement in the regulated proteolysis of the transcriptional co-activator β-
catenin. In the absence of Wnt signaling, a protein complex, known as β-catenin 
destruction complex, regulates signaling and β-catenin levels. This complex is 
composed of adenomatous polyposis coli (APC), glycogen synthase kinase 
(GSK3β), cyclin-dependent kinase (CK1α, CK1δ and CK1ϵ) and axis inhibition 
protein (Axin1/2). Axin has been proposed as the concentration limiting 
component in the regulation of the β-catenin degradation (Huang et al, 2009).  
GSK3β phosphorylates β-catenin and causes its proteasomal degradation (Hart et 
al, 1999). The Wnt signaling pathway recruits the GSK3β and Axin to the plasma 
membrane. Due to this the β-catenin destruction complex dissociates and non-
phosphorylated β-catenin levels increase in the cells (Fig. 5). Truncation 
mutations in either tumor suppressor gene APC or CTNNB1 (the gene encoding 
β-catenin) have been implicated in 95 % of the colorectal cancers. Tankyrases 
play a central role in the regulated degradation of the β-catenin by modifying 
Axin. They regulate the levels of Axin, RNF146 and themselves via PARsylation 
reaction (Callow et al, 2011; Huang et al, 2009; Waaler et al, 2012). RNF146 is a 
ring-domain E3 ubiquitin ligase that acts as a positive regulator of Wnt signaling. 
It controls the degradation of Axin, tankyrases and itself by recognizing the 
tankyrase-mediated PARsylation (Fig. 5) (Callow et al, 2011; Zhang et al, 2011). 
Hence, tankyrases are the key molecules in maintaining the cellular levels and 
turnover number of β-catenin. It has been reported that inhibition of the catalytic 
activity of tankyrases cause the inhibition of the Wnt signaling and consequently 
the stabilization of the Axin (Huang et al, 2009). Notably, tankyrase-Axin 
interactions are also involved in insulin-stimulated glucose uptake.       
1.4.3 GLUT4 vesicle translocation  
GLUT4 is one type of a glucose transporter, which is mostly expressed in the 
skeletal muscles and adipose tissues (Hou & Pessin, 2007; Leney & Tavaré, 
2009). In the basal state, GLUT4 resides in the intracellular membrane 
components known as GLUT4 storage vesicles (GSVs). Interestingly, GSVs also 
contain a tankyrase binding protein IRAP (Chi & Lodish, 2000). GLUT4 and 
IRAP play a central role in the insulin-stimulated glucose uptake (Guo et al, 
2012). When blood glucose levels rise, insulin secretion is elevated subsequently 
stimulating the glucose uptake by inducing rapid translocation of GLUT4 
vesicles to the cell membrane. It has been demonstrated that TNKS1 binds to 
IRAP and facilitates the exocytosis of GSVs. Knocking down of either TNKS1 
or IRAP suppresses the GLUT4 translocation (Yeh et al, 2007).  
Immunoprecipitation experiments and in vitro pull down assays indicated that 
TNKS2 forms a ternary complex with Axin and kinesin motor protein (KIF3A) 
(Guo et al, 2012). To confirm that TNKS2-AXIN-KIF3A complex is required for 
GLUT4 translocation in response to insulin, immunofluorescent staining was 
carried out in differentiated adipocytes cells expressing high levels of GLUT4. 
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Results showed that in the absence of insulin, the ternary complex co-localizes 
with GLUT4 in the adipocytes. However, in the presence of insulin, the 
distribution of GLUT4 was observed at the cell surface (Guo et al, 2012). 
Knocking down the each component of the ternary complex indicated that all the 
components are essential for the active transport of GLUT4, and absence of any 
of them could suppress the translocation of GLUT4 and glucose uptake following 
insulin stimulation (Guo et al, 2012).  
In the absence of insulin, tankyrase proteins PARsylate themselves, axin and 
GLUT4, causing their subsequent ubiquitination. Insulin signaling inhibits 
tankyrase activity and this further stabilizes the ternary complex (Guo et al, 
2012). The potent tankyrase inhibitor XAV939 seems to have similar effect as 
insulin, which indicated that tankyrase PARsylation activity plays a negative role 
in mediating the stability of translocation complex. Although the role of 
tankyrases in this particular process is elusive and needs further research (Guo et 
al, 2012).    
1.4.4 Mitosis 
In the earlier studies, tankyrases have been shown to PARsylate several proteins 
that are involved in mitosis (Chang et al, 2005a, 2005b; Kim et al, 2012). This 
suggests that tankyrases have a functional role in the cell cycle. TNKS1 localizes 
at the spindle poles during mitosis and its activity is also upregulated during the 
process. Knocking down TNKS1 by RNA interference causes pre-anaphase 
arrest (Dynek & Smith, 2004). Notably, some of the proteins involved in mitosis 
and modified by tankyrases are NuMA (Chang et al, 2005a, 2005b; Dynek & 
Smith, 2004) and Miki (Ozaki et al, 2012). NuMA is a nuclear protein, which is 
associated with mitotic apparatus and shuttles between the nuclear matrix in 
interphase and the spindle poles in mitosis. NuMA plays a central role in many 
processes such as in the nuclear structure, spindle assembly, and nuclear re-
formation (Chang et al, 2005b). PARsylation of NuMA by tankyrases has been 
proposed to be essential for maintaining proper spindle polarity (Chang et al, 
2005a; Hsiao & Smith, 2008). Miki is a mitotic kinetics regulator that resides in 
the Golgi apparatus and translocate to the mitotic centrosome in late G2 and 
prophase (Ozaki et al, 2012). Depletion of Miki induces prometaphase arrest that 
consequently leads to chromosome scattering and pseudo metaphase. TNKS1 is 
activated by phosphorylation through GSK3β (Yeh et al, 2006a) and it 
PARsylates Miki (Ozaki et al, 2012). This modification is required for the 
translocation of Miki from Golgi apparatus. Tankyrases and PARsylated Miki 
translocate together in the late G2 to prophase where Miki anchors the scaffold 
protein CG-NAP (centrosome and Golgi localized protein kinase N-associated 
protein).  
TNKS1, Miki and CG-NAP are required for the formation of robust microtubules 
and subsequently for the normal movement of chromosomes in the 
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prometaphase. Their downregulation leads to prometaphase defect (Ozaki et al, 
2012). During interphase, TNKS1 forms a complex with GDP-mannose 4,6–
dehydratase (GMD). Unlike other binding partners, GMD does not get modified, 
but it inhibits TNKS1 activity and this complex may serve as the ready pool of 
inactive TNKS1 (Bisht et al, 2012). It has also been proposed that TNKS1 
binding to NuMA or TRF1 is inhibited by GMD and phosphorylation of TNKS1 
via GSK3β might have a role in breaking the TNKS1-GMD complex (Bisht et al, 
2012). Along with GSK3β, another kinase protein Polo-like-kinase (PLK1) is 
also identified as tankyrase binding partner at the telomeres. PLK1 is a 
serine/threonine kinase that increases the TNKS1 stability and its PARsylating 
activity at the telomeres by phosphorylation reaction (Ha et al, 2012). ARTD3 
also plays a critical role in the stabilization of the mitotic spindle and in 
promoting the telomere integrity. It is found to be a positive regulator of TNKS1 
mediated modification of NuMA in a DNA independent manner and also 
enhance the automodification of TNKS1 (Boehler et al, 2011).        
Another aspect of tankyrases that make them important players in the mitosis is 
their function at the centrosome. Tankyrases have been implicated in the 
regulation of centrosome duplication process which is critical for the genome 
integrity. A centrosomal P4.1-associated protein (CPAP) is required for the 
normal centrosome function in the human cells. Earlier, it was reported that down 
regulation of CPAP prevented centrosome duplication and its overexpression led 
to aberrant centriole elongation, supernumerary centrioles and spindle 
multipolarity (Kim et al, 2012). Thus, regulation of CPAP levels is very critical 
for the normal cell cycle. Notably, CPAP is a binding partner of tankyrases and 
its stability and function at the centrosomes is regulated by the tankyrase-
mediated PARsylation reaction.  
Altogether, the involvement of the tankyrases in the aforementioned processes 
makes them key players in the mitosis and cell cycle. 
1.4.5 Proteasome regulation  
ADP-ribosylation by tankyrases is identified as a regulator of protein degradation 
by the ubiquitin-proteasome system (UPS) (Cho-Park & Steller, 2013). Protein 
degradation is the primary means for the removal of misfolded and potentially 
toxic proteins. Abnormal protein degradation is associated with several human 
diseases such as muscle-wasting diseases, neurodegenerative disorders and 
cancer (Glickman & Ciechanover, 2002; Goldberg, 2007; Hershko & 
Ciechanover, 1998). The UPS mainly carries out selective protein degradation. In 
this process, proteins are tagged with the polyubiquitin chains and these tagged 
proteins are further hydrolyzed into small peptides by the 26S proteasome. The 
26S proteasome is a large protease complex, composed of 20S core particle and 
19S regulatory particles, and its activity is regulated by large number of loosely 
associated proteins. One such regulator is proteasome inhibitor 31 (PI31) that 
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was identified as an inhibitor of 20S core particle and as an activator of 26S 
proteasome activity (Bader et al, 2011; Chu-Ping et al, 1992; McCutchen-
Maloney et al, 2000).  
Tankyrases modulate PI31 activity via PARsylation and this modification further 
reduces the affinity of this protein for binding to the 20S particle (Cho-Park & 
Steller, 2013). Moreover, chaperons, dp27 and dS5b, associated with 19S 
particles are also found as the binding partners of PI31. In this particular process, 
tankyrase-mediated PARsylation causes increased binding of PI31 to dp27 and 
dS5b and subsequently promotes the 26S proteasome assembly. Inhibition of 
tankyrases reduce the 26S proteasome activity in both Drosophila and 
mammalian cells (Cho-Park & Steller, 2013). Therefore, tankyrase activity plays 
an important role in the regulation of protein degradation via UPS and abnormal 
degradation could be targeted by tankyrase inhibition.  
1.5 Role of tankyrases in cancer 
Increased expression of the tankyrases has been detected in many cancers such as 
fibrosarcoma (Smith et al, 1998), ovarian cancer (McCabe et al, 2009), 
glioblastoma (Shervington et al, 2007), pancreatic adenocarcinoma (Zhao et al, 
2009), breast cancer (Gelmini et al, 2004; McCabe et al, 2009; Smith et al, 
1998), lung cancer (Busch et al, 2013), astrocytoma (Tang et al, 2012), 
transitional cell carcinoma of the bladder (Gelmini et al, 2004), gastric cancer 
(Gao et al, 2011) and colon cancer (Gelmini et al, 2006). However, a study on 
the colon cancer showed that TNKS1 was up-regulated and TNKS2 was down-
regulated in comparison to the normal cells (Shebzukhov et al, 2008). 
Furthermore, mutations such as deletion or duplication of nucleotides in the DNA 
coding sequence of the tankyrases are also seen in gastric and colorectal cancers 
(Kim et al, 2011). A recent study has also established tankyrases as potential 
drug targets in the colorectal carcinomas (CRCs) in vitro and in vivo (Lau et al, 
2013). Two inhibitors, G007-LK and G244-LM, were used to specifically inhibit 
tankyrases in order to attenuate Wnt signaling and consequently promote the β-
catenin degradation. G007-LK binds to the adenosine site of the tankyrases, 
whereas G244-LM binds to the nicotinamide site.  
These tankyrase inhibitors completely blocked the ligand driven Wnt signaling in 
the normal cells and displayed approximately 50 % inhibition in the APC 
mutation-driven signaling (Lau et al, 2013). Out of the two compounds, G007-
LK was more selective and was also able to inhibit in vivo tumor growth in an 
APC-mutant CRC model. In some of the KRAS-mutant cell lines, G007-LK did 
not show single-agent activity for the inhibition of the clonogenic cell growth. 
However, it potentiated the effect of mitogen activated kinase (MEK) inhibitor 
(Lau et al, 2013). Recently, tankyrases were also implicated in lung cancers 
(Casás-Selves et al, 2012). The most common type of lung cancer is 
adenocarcinoma, which is the result of the mutations in the epidermal growth 
factor receptor (EGFR) gene. Although, EGFR inhibitors are sufficient for the 
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treatment, there are some cases, where cancer cells developed a particular escape 
mechanism to promote the cell survival. One such mechanism is via Wnt 
signaling pathway which is positively regulated by tankyrase-mediated 
modifications. Inhibition of tankyrases, in these cases, has increased the activity 
of EGFR inhibitors both in vivo and in vitro (Casás-Selves et al, 2012). In 
addition, tankyrases are also involved in the breast cancers associated with the 
decreased expression of either breast cancer type 1 susceptibility protein 1 
(BRCA1) or BRCA2. Tankyrase inhibition in these cells was synthetic lethal and 
was characterized by the increase in the centrosome amplification, whereas there 
was no effect in the control cells. The basis of the mechanism causing this 
synthetic lethality is so far not understood. (McCabe et al, 2009).    
1.5.1 Role of tankyrases in viral infections              
Tankyrases are also implicated in viral infections such as in the replication of 
herpes simplex virus (HSV) (Li et al, 2012). Tankyrase acts as a target of HSV 
and undergoes phosphorylation, nuclear translocation and degradation. Post-HSV 
infection, TNKS1 was phosphorylated by MAPK and was also recruited to the 
nucleus of HSV infected cells. TNKS1 co-localized with the HSV-infected cell 
polypeptide (ICP0) in the nucleus and their interaction is required for the HSV 
replication. In the normal cells, ICP0 regulates nuclear localization of TNKS1, 
whereas in case of infection, viral protein expression leads to the recruitment of 
TNKS1 into the nucleus. The replication of herpes simplex virus type 1 (HSV-1) 
was impaired when both TNKS1/2 were knocked out using siRNA. Similar 
effects were seen when tankyrase enzymatic activity was inhibited using 
XAV939 treatment. These results indicated that HSV-1 replication was promoted 
by the catalytic activity of tankyrases (Li et al, 2012). In contrast, tankyrase has 
been shown to inhibit the replication of the Epstein-Barr virus origin of plasmid 
(Deng et al, 2005). 
1.5.2 Role of tankyrases in obesity and other diseases      
Tankyrases have also been proposed to be associated with obesity. Previously, 16 
genetic loci have been linked to obesity using genome-wide association studies 
(Hinney & Hebebrand, 2009; Hofker & Wijmenga, 2009; Walley et al, 2009). In 
addition to this, during a meta-analysis study, two new genetic loci were 
identified that were relevant for early onset extreme obesity. One of them is 
present at a genetic locus between the tankyrase and methionine sulfoxide 
reductase, a gene that might be responsible for the obesity (Scherag et al, 2010).  
Tankyrase knockout mice exhibit an increase in energy utilization and insulin-
stimulated glucose utilization (Yeh et al, 2009). Tankyrases are also implicated 
in fibrotic disease as their inactivation by XAV939 or SiRNA effectively 
abolished the Wnt signaling and demonstrated antifibrotic effects (Distler et al, 
2012). Cherubism, an autosomal-dominant syndrome, is also shown to be related 
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with the tankyrases. This disease is caused by the mutation in a gene that encodes 
3BP2 (an adaptor protein), and 3BP2 stabilization is regulated by the tankyrase-
mediated PARsylation reaction. Mutated 3BP2 escapes the tankyrase-mediated 
modification that further causes the stabilization of 3BP2 and subsequently 
signaling pathways get inappropriately activated. Therefore, cherubism is the 
result of the loss of interaction between the tankyrases and 3BP2 (Guettler et al, 
2011; Levaot et al, 2011). 
1.6 Drug development and available ARTD inhibitors 
In this thesis, early drug-discovery efforts are made in order to identify potent 
and selective tankyrase inhibitors. Following sections will describe the general 
properties required for a drug candidate, clinical phases which a drug candidate 
has to pass, and finally summary of the discovery process that has led to 
currently available ARTD inhibitors.   
1.6.1 Properties of a drug candidate and screening strategy 
Drug designing is the process of finding out new small molecules that would be 
able to change the biological activity of the drug target and would also have 
therapeutic potential. Drug targets could be enzymes, receptors, ion channels, 
transporters or DNA. Before a drug is designed, there should be a method to 
screen the compounds against drug target. After establishing the testing 
procedures and finding the lead compound, structure-activity relationship studies 
are done and a pharmacophore is identified. Further, targeting interactions are 
modified using drug designing approaches that include laboratory experiments 
and computer aided methods.   
In the laboratory experiments, chemical libraries containing large number of 
compounds are screened against the target molecule using biochemical assay. 
Computer aided methods could be further divided into three subclasses; 
inspection-based, virtual screening, and de novo generation. In inspection-based 
method, known molecules that bind the site are modified to become inhibitors. 
Virtual screening involves the screening of small-molecule libraries, in order to 
identify those structures, which are most likely to bind to the drug target. De 
novo generation method involves screening of small fragments of compounds 
and scoring them according to their interactions in the binding cavity. Later a 
complete compound is synthesized in the laboratory using screened small 
fragments.  
However, it may take many years of research and development before a drug 
reaches the market. 
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1.6.2 Pharmacodynamics and pharmacokinetics 
The pharmacological activity of a compound is defined by four benchmarks 
which are absorption, distribution, metabolism and excretion. These are generally 
abbreviated as ADME in pharmacology. A rule that describes these properties of 
a drug lead and also determine the druglikeness of the compound is known as 
Lipinski’s rule of five (LRO5). This rule is followed during the drug discovery 
and helps in the stepwise optimization of the hit compounds. LRO5 facilitates the 
research process and increase the probability of converting a drug lead into an 
orally active drug. Rule of five is as follows: 
I. There should not be more than 5 hydrogen bond donors. 
II. There should not be more than 10 hydrogen bond acceptors.  
III. Molecular mass should be less than 500 daltons.   
IV. logP value should not be greater than 5.  
1.6.3 Clinical phases 
Drug candidates pass through different clinical phases before they reach the 
market. These phases include preclinical studies, phase 0, and phase I to phase V. 
In the preclinical studies, in vitro and in vivo experiments are performed in order 
to collect the information about the potency, efficacy, pharmacokinetics and 
safety of the compound. In phase 0 trials, small doses of drug is given to small 
population (10-15) of humans. The aim of phase 0 trial is to gather preliminary 
data about whether drug reaches the diseased cells, how drug behaves in the body 
and how diseased cells respond to the drug. This phase helps in speeding up the 
drug-development process.  Phase I trails are generally performed on healthy 
individuals (20-100) in tightly controlled clinics. This phase is designed to collect 
data about the safe dose range, side effects, pharmacokinetics and 
pharmacodynamics of a drug.  
Drugs that pass phase I trial, enter in phase II, where biological activity of the 
drug is tested. These tests are performed on a larger group (100-300) of patients 
and volunteers, and information about efficacy and toxicity is collected. In phase 
III trials, effectiveness of the drug is compared with the already existing standard 
treatment. This phase is also known as pre-marketing phase and drugs are 
required to be effective at this stage in order to obtain approval from the 
appropriate regulatory agencies. Phase IV trials involve the pharmacovigilance 
after drug has been shown to work and has been granted a license. Aim is to find 
out the long term risks and benefits over the larger patient population and longer 
time periods. Phase V is designed to determine if the significance of the new 
drug candidate is realized in clinical practice.   
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1.6.4 PARP inhibitors and selective tankyrase inhibitors 
The PARP/ARTD family proteins are involved in several cellular processes and 
critical functions of some of the members has made them potential therapeutic 
targets. Nicotinamide, which is released during the PARsylation reaction was the 
first identified ARTD inhibitor (Clark et al, 1971). In 1980, more ARTD 
inhibitors (substituted benzamides) were identified (Purnell & Whish, 1980) and 
since then several novel scaffolds have appeared in context of various areas such 
as cancer therapy, cardiac ischemia, rheumatoid arthritis, stress response and 
diabetes mellitus (Gonzalez-Rey et al, 2007; Hilton et al, 2013; Pacher et al, 
2002; Pyriochou et al, 2008; Szabó et al, 1997; Zingarelli et al, 1998). Most of 
the inhibitors discovered to date mimic nicotinamide and bind to the 
nicotinamide-binding site.  
However, it was recently reported that some of the inhibitors were binding to 
adenosine site of tankyrases (IWR-1 and JW55). The most studied family 
member, ARTD1, has also been the most actively targeted ARTD member in the 
drug discovery research. However, because of the conserved nicotinamide-
binding site, it is very likely that these inhibitors would inhibit other ARTD 
members also. As this research was on going, other ARTDs, such as tankyrases, 
were also getting attention because of the growing understanding of their 
biological roles. Notably, there were no selective tankyrase inhibitors available 
when this PhD project was started. During the project several groups including 
ours published many tankyrase inhibitors (Bregman et al, 2013a, 2013b; Huang 
et al, 2006; James et al, 2012; Shultz et al, 2013a, 2013b, 2012; Waaler et al, 
2011; Yashiroda et al, 2010, 2010). Like ARTD1, the vast majority of the 
identified tankyrase inhibitors bind to the nicotinamide site but it was the 
different conformations of D-loop that provided the route for the development of 
selective tankyrase inhibitors by allowing binding of compounds to the adenosine 
site.   
Inhibitor studies were further facilitated by the availability of the crystal 
structures of the catalytic domains (PDB codes: TNKS1, 2RF5; TNKS2, 3KR7) 
(Karlberg et al, 2010; Lehtiö et al, 2008). Compounds XAV939 and IWR-1 were 
found to inhibit Wnt signaling through tankyrase inhibition (Huang et al, 2009). 
Later crystal structures of TNKS2 in complex with XAV939 and IWR-1 were 
solved that helped in the understanding of their structure-activity relationships 
(Karlberg et al, 2010; Narwal et al, 2012b).  
1.6.5 Tankyrase inhibitors binding to the nicotinamide site  
The nicotinamide site is targeted by most of the tankyrase inhibitors such as 
XAV939 (Fig. 6) and they share some common features. Tankyrase and ARTD 
inhibitors form typical hydrogen bonds with Gly1032 and Ser1068 which are 
present at the bottom of the pocket in TNKS2 (Gly1185 and Ser1121 in TNKS1). 
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Another shared interaction is π-π stacking with Tyr1071 of TNKS2 (Tyr1224 in 
TNKS1). There has been efforts to optimize inhibitors binding to nicotinamide 
site (Haikarainen et al, 2013b; Shultz et al, 2013a, 2012).  
1.6.6 Adenosine site and dual-site binding inhibitors 
Some of the inhibitors do not contain nicotinamide motif, one such compound is 
IWR-1 (Fig. 6), which was discovered in Super top flash (STF) luciferase assay. 
STF assay is a cell-based assay that utilizes a construct containing luciferase TCF 
(T Cell Factor) reporter plasmid that responds to the Wnt/β-catenin pathway 
activity. IWR-1 was found as an antagonizer of Wnt signaling and later 
established as a selective tankyrase inhibitor (Huang et al, 2009). Complex 
crystal structure of TNKS2 with IWR-1 showed that it binds to the adenosine site 
(Narwal et al, 2012b).  
 
 
Figure 6. Chemical structure of NAD+ along with the known potent TNKS inhibitors 
IWR-1 and XAV939. IWR-1 binds to adenosine site of the protein molecule and 
XAV939 binds to nicotinamide site. Different regions present in IWR-1 are mentioned. 
The molecular basis of its interaction will be discussed later in the results and 
discussion chapters. Additionally, some more inhibitors were reported to bind to 
the adenosine site such as WIKI4, JW55, JW74, G007-LK (Bregman et al, 
2013a, 2013b; Haikarainen et al, 2013b; Voronkov et al, 2013). One of the 
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ARTD inhibitors, PJ34, has been shown to bind to both the adenosine and the 
nicotinamide sites with one molecule binding to each site (Kirby et al, 2012). 
Recently, a novel class of tankyrase inhibitors were discovered that bind to both 
the nicotinamide and adenosine sites (Shultz et al, 2013a). These findings have 
led to the development of several chemical scaffolds as selective and potent 
tankyrase inhibitors.  
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2 Aims of the study 
The primary aim of this thesis work was to develop selective and potent 
tankyrase inhibitors. Recognition of key roles that tankyrase play in multiple 
pathological conditions, including cancer, has led to efforts to develop effective 
inhibitors against them, as there were no specific tankyrase inhibitors available 
when this study was started. In order to identify potential hit compounds, 
chemical libraries were screened and potencies were measured using biochemical 
assay. Complex crystal structures with ligands were determined using 
macromolecular X-ray crystallography. 
More specifically, in paper I, the aim was to develop an assay for human 
tankyrases that could be utilized for the screening of chemical libraries. Another 
plan was to validate the assay conditions and to carry out a validatory screening 
to verify that assay is working. Based on these results, in paper III, the goal was 
to screen a larger flavonoid library and discover novel inhibitors of tankyrases 
among different classes of flavonoids. In paper IV, the aim was to screen a small 
library of flavones with single substitution because flavones were the only class 
of flavonoids that was inhibiting tankyrase effectively. To evaluate the efficacy 
and selectivity of the hit compounds, we aimed to test compounds in cell based 
assay and against a panel of ARTD-family members available in our laboratory. 
In paper III and IV, we were aiming to measure the potencies of hit compounds 
and solve the co-crystal structure of the ligands with tankyrase 2 catalytic domain 
to establish the structure-activity relationship. 
In Paper II, the aim was to solve a complex crystal structure with a potent 
tankyrase inhibitor, IWR-1, as this compound does not contain nicotinamide-
binding motif. Another goal was to shed light on the molecular interactions 
between the substrate NAD+ and tankyrases. There was no structural information 
available about the binding of substrate with any of the ARTD superfamily 
members, and substrate complex could give important information about the 
enzyme function. In paper V, aim was to evaluate the inhibition of tankyrases by 
known ARTD inhibitors using activity assay and protein X-ray crystallography.  
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3 Materials and methods 
The materials and methods that were used in studies are described in full details 
in the respective publications (I-V). Only a short description is given here on the 
experimental approaches used.  
3.1 Expression vectors (I-V) 
The expression constructs of the catalytic fragment of human TNKS1 consisting 
of SAM and ARTD domain (1030-1317) and TNKS2 ARTD domain (946-1161) 
were gifts from Structural Genomics Consortium (SGC), Stockholm, Sweden. 
The coding sequences were cloned to a pNIC28-Bsa4 plasmid, which contains an 
N-terminal 6x-histag followed by a TEV protease cleavage site before the 
tankyrase sequence. TNKS2 fragment containing the SAM and ARTD domain 
and ARTD1, ARTD2, ARTD4, ARTD7, ARTD10, ARTD12 were either 
obtained from SGC or produced in our laboratory by the members of the research 
group (Haikarainen et al, 2013b; Narwal et al, 2013b).  
3.2 Protein expression and purification (I-V) 
Protein expression for all the tankyrase constructs was conducted in the E. coli 
(Rosetta 2 DE3) cells using terrific broth auto-induction media containing trace 
elements and supplemented with 8 g/L glycerol and antibiotics. Larger cultures 
were initiated with the overnight pre-culture and were allowed to grow at 37 
ºC/220 rpm until OD600 reached 1. Next, the cultures were incubated overnight in 
an incubator shaker set at 18 ºC/180 rpm. The cells were collected by 
centrifugation and suspended in the lysis buffer. The purification of the produced 
proteins was usually done by two-step process, using nickel-affinity (Ni-affinity) 
chromatography and followed by size exclusion chromatography (Haikarainen et 
al, 2013b; Narwal et al, 2013a, 2013b, 2012a, 2012b; Venkannagari et al, 2013). 
In brief, Cells were lysed with lysozyme (2 µg/mL) and sonication, and solution 
was cleared by centrifugation. Supernatant was filtered through 0.45-µm filters 
and sample was loaded on HisTrap HP column (GE Healthcare) which was 
preequilibrated with binding buffer. Column was first washed with binding 
buffer and subsequently with washing buffer. Protein was eluted with an elution 
buffer having 250 mM imidazole and pooled fractions were loaded to size 
exclusion column (Hiprep 16/60 Sepharyl S-100 HR or Superdex S-200 10/30; 
GE Healthcare). Fractions from size exclusion chromatography were analyzed on 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Finally, protein preparations were divided to small aliquots and flash frozen 
using liquid N2 into -70 ºC freezer.  
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3.3 Activity assay (I-V) 
The fluorescence assay was adapted from the article by (Putt & Hergenrother, 
2004). This assay measures the remaining substrate after the enzymatic reaction. 
The substrate consumption was quantified by converting the NAD+ into a stable 
fluorescent condensation product upon treatment with acetone followed by 
heating in the acidic conditions. Reaction was carried out on black polypropylene 
U-shaped 96-well plate. After the enzymatic reaction, 20 µL of 20 % 
acetophenone and 20 µL of 2 M KOH were added. The plate was incubated at 4 
ºC for 10 minutes and 90 µL formic acid was added after the incubation. The 
plate was transferred to 110 ºC oven for 5 minutes and read after 30 minutes. 
Later the assay was modified and plate was incubated at RT instead of 4 ºC, also 
step involving heating in the oven was omitted. Instead all the assay steps were 
performed at room temperature and plate was read 20 minutes after adding 
formic acid. Plate readers used were Varioskan flash (Thermo Fisher Scientific), 
Fluoroskan Ascent FL (labsystems) or Tecan plate reader (Infinite M1000 Pro 
and Infinite M200 Pro) at an excitation/emission wavelength of 355/460 nm 
using the filters and excitation/emission wavelength of 372/444 nm using the 
monochromators.   
3.4 Optimization of assay conditions and assay 
repeatability (I, III) 
Assay conditions were optimized by testing the effect of different buffer 
components on the enzymatic activity (Fig. 3B and Table 1 in I). Different 
NAD+ concentrations were also tested and their effect on the enzymatic reaction 
was examined. As compounds were stored in DMSO, therefore, DMSO tolerance 
of the assay was studied. Separate controls were used for each condition. The 
incubation time varied depending on the protein batch used but the aim was to 
reach approximately 25 % conversion in order to clearly see the effects of 
different reagents.  
The assay performance was determined by measuring the maximal and minimum 
signal. To evaluate the positional effects during the incubation, well-to-well 
variations were measured. The plate-to-plate and day-to-day variations were also 
calculated by measuring two plates on the same day and two plates on different 
days. Assay repeatability was tested manually as well as using a pipetting robot 
(Fig. 4A and Table 2 in I). Assay quality was evaluated using following 
statistical parameters: screening window coefficient (Z′ factor), signal-to-
background (S/B) ratio (Zhang et al, 1999), signal to-noise (S/N) ratio (Bollini et 
al, 2002), and coefficient of variation of the assay (CVA) (Iversen et al, 2006). Z´ 
is a dimensionless term, which is used to evaluate, compare and validate 
bioassays. The acceptance criteria for Z´ is as follows; Excellent: Z´ > 0.5, Do-
able: 0 < Z´ < 0.5, Yes/No assay: Z´= 0, Unacceptable: Z´ < 0 (Iversen et al, 
2006; Zhang et al, 1999).  
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Final buffer used for TNKS1 and TNKS2 constructs containing ARTD and SAM 
domain was 50 mM Bis Tris propane, pH 7 supplemented with 0.01 % Troton X-
100 and 0.5 mM TCEP. Whereas, buffer used for TNSK2 fragment containing 
only catalytic domain was 50 mM Bis Tris propane, pH 7 supplemented with 2 
mM NiCl2 and 1 mM TCEP.    
3.5 Screening and potency measurements (I, III, IV, V) 
Compounds were stored in DMSO at -20 ºC and they were diluted in the assay 
buffer prior to the experiments. Screening of the compounds was done in 
duplicates and separate controls were used for each compound. The final 
concentration of the compounds in the well was 10 µM or 1 µM. Hits were 
retested at 1 µM in triplicates to identify possible false positives.  
The inhibitory potency of the hit compounds was measured in quadruplicates and 
in most of the cases; the experiment was repeated three times. Starting inhibitor 
concentrations were 100 µM or 10 µM and half log dilution was used. Reaction 
time was set to achieve less than 30 % conversion. Following terms are used in 
this thesis: Half maximal inhibitory concentration (IC50-value) is defined as the 
concentration of compound required in order to inhibit 50 % activity of the 
enzyme, Half maximal effective concentration (EC50-value) is the concentration 
of a compound where 50 % of its maximal effect could be observed. Potency is 
the measure of the activity of a drug in a biochemical assay and in this thesis 
sometimes the term ‘potency’ has been used to mention IC50-value. Standard 
deviation (SD) is the measure of variation from the mean.  
Ligand efficiency (LE) is defined as the binding affinity of a ligand in relation to 
number of non-hydrogen atoms and is calculated as LE = 1.4 (-logIC50/N), where 
N is number of non-hydrogen atoms, and lipophilic efficiency (LipE) is a 
parameter used in drug design to link the potency and lipophilicity of compound 
and can be calculated as LipE = pIC50 – logP, where pIC50 is –log10(IC50) and 
logP is lipophilicity of the drug. IC50 curves were fitted with Graphpad Prism 
using sigmoidal dose response curve and four variables.  
3.6 Western blot method (I, II) 
A western blot method was used to confirm the results from the homogenous 
assay. Biotinylated NAD+ (bioNAD+) (1 µM) was used as the substrate in the 
enzymatic reaction. Laemmli buffer (Bio-rad) was added to stop the reaction and 
the sample was heated at 98 ºC for 5 minutes. Next, SDS-PAGE was run and gel 
was blotted onto the nitrocellulose membrane. Blocking was performed overnight 
with 1 % casein (Bio-Rad). Modified proteins were detected using streptavidin-
conjugated horseradish peroxidase.  
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3.7 Crystallization and crystallography (II-V) 
TNKS2 catalytic domain was used for crystallization. Chymotrypsin and 2mM 
TCEP were added to the purified TNKS2 protein solution and it was 
concentrated to 5.8 mg/mL. Chymotrypsin was added (one part to 100 parts by 
concentration of TNKS2), as protein was precipitating during centrifugation. 
Also, crystal form of chymotrypsin cleaved protein made it possible to soak 
inhibitors. Crystallization was done using sitting drop vapor diffusion method. 
The well solution contained 0.2 M Li2SO4, 0.1 M Tris-HCl, pH 8.5, and 24-26 % 
PEG 3350.  Protein solution was mixed with the well solution in 2:1 or 1:1 ratio, 
and crystals appeared with in a week at 4 ºC. Pipetting robot (mosquito) was used 
in order to minimize the protein consumption and final size of the drops varied 
from 200 nanolitres to 300 nanolitres. Co-crystal structures were obtained by 
soaking the TNKS2 crystals in the well solutions containing the inhibitors. 
Compounds were soaked overnight except for EB-47 and rucaparib, for which 
the soaking time was three months. The inhibitor concentration used was in the 
range of 100 µM - 10 mM. Additionally, 250 mM NaCl was also added to the 
soaking solution in order to prevent the protein crystals from osmotic shock as 
there was salt present in the protein solution. Crystals were quickly dipped into a 
cryosolution supplemented with inhibitor, 250 mM NaCl and 20 % of glycerol, 
before flash freezing them in the liquid N2 for data collection.  
Diffraction data was collected at the synchrotrons situated in France (ESRF, 
Grenoble), UK (Diamond Light Source, Oxfordshire) or at the home source 
Bruker Microstar X-ray generator with PLATINUM CCD detector. Data were 
processed with XDS (Kabsch, 2010) and Proteum 2 suite (Bruker). Crystals 
belonged to the C2221 or P41212 space groups. The phases were determined with 
the molecular replacement program Molrep (Vagin & Teplyakov, 2010) from 
CCP4 program suite (Dodson et al, 1997). Apo-TNKS2 structure (PDB code: 
3KR7) or TNKS2-nicotinamide co-crystal structure (PDB code: 3U9H) were 
used as search models. Water molecules and ligands were deleted from the 
models prior to molecular replacement. Refmac5 (Murshudov et al, 2011) from 
CCP4 program suite was used for molecular replacement and refinement. Manual 
building of the models was performed using Coot (Emsley & Cowtan, 2004). 
Validation of the results was performed using an online tool MolProbity from 
Duke University.       
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4 Results 
The results will be summarized in this section, more detailed description of the 
results is available in the original articles (I-V). 
4.1 Adaptation of an assay for screening the compounds 
4.1.1 Protein expression and purification (I-V)  
To determine the optimal media for TNKS1 protein expression, different culture 
media for E. Coli (Luria broth, 2 × YT broth, super broth, Terrific broth) were 
tested in small scale (200 mL) using isopropyl-β-D-thiogalactoside (IPTG) 
induction or autoinduction methods. Protein fractions purified using Ni-affinity 
chromatography were run on SDS-PAGE to compare expression levels. Terrific 
Broth autoinduction media gave the best expression in comparison with other 
culture media. In case of TNKS1, Ni-affinity purification step yielded pure 
protein. However, gel filtration (GF) purification step increased the enzyme 
activity by four fold. Size exclusion chromatography revealed that the 37 kDa 
protein eluted as a high molecular weight (approx. 600 kDa) species in 
agreement with the reported multimerization. TNKS2 construct containing the 
catalytic domain was purified similarly using Ni-affinity chromatography and gel 
filtration methods (Narwal et al, 2012b). TNKS2 fragment containing the SAM 
domain in addition to the catalytic domain was purified in two steps using Ni-
affinity and cation exchange chromatography (Haikarainen et al, 2013b; Narwal 
et al, 2013b; Venkannagari et al, 2013). 
4.1.2 Assay optimization (I, III) 
The best assay conditions for TNKS1 (containing SAM and ARTD domain) and 
TNKS2 (containing ARTD domain) were determined by testing various buffer 
types and components in the enzymatic assay. Different buffers were used to 
measure the protein activity in a pH range from 3.5 to 9. Based on the substrate 
conversion, protein was active over the pH range of 5-8 but the best activity was 
observed at pH 5.5 (Fig. 3A in I). However, pH 7 was selected for further 
optimization as this pH was close to the physiological pH and that also made it 
suitable for screening the compound libraries. Moreover, different buffers and 
buffer components such as divalent cations, reducing agents, detergents, salts, 
glycerol and BSA etc. were tested at pH 7 (Table 1 in I and Fig. 3B in I). The 
final buffer used for TNKS1 was 50 mM Bis Tris propane supplemented with 
0.01 % Triton-X-100 and 0.5 mM TCEP (Tris (2-carboxyethyl) phosphine) (Fig. 
3B in I). The same buffer was used for TNKS2 fragment containing catalytic and 
SAM domains. In case of TNKS2 fragment containing only catalytic domain, 50 
mM Bis Tris propane supplemented with 2 mM NiCl2 and 1 mM TCEP (Tris (2-
carboxyethyl) phosphine) was found to be the best for activity. The TNKS1 
automodification activity was protein concentration and incubation time 
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dependent. However, diluting it to lower concentrations led to loss of the activity 
(Fig. 3C,D in I). The rate of substrate conversion was also found to be linear 
with time when the conversion was lower than 50 % (Fig. 3D in I). 
4.1.3 Assay validation (I, III) 
In order to validate the assay, plates containing the maximal and minimal signals 
were analyzed. The results showed that the signals followed binomial distribution 
(Fig. 4A in I). A good dynamic signal range was observed and the qualitative 
parameters (S/B, S/N and CVA) were calculated (Table 2 in I and Table 1 in 
III). Z´ value for the manual assay for both TNKS1 and TNKS2 was 0.72. Thus, 
Z´ value along with the calculated parameters clearly indicated the suitability of 
the assay for the compound screenings. Different NAD+ concentrations were 
tested for TNKS1 and 500 nM was used as it gave the best results (Z´ > 0.7). 
However, even at lower NAD+ concentrations, assay was found to be useful (Z´ > 
0.6). Assay performance was not affected when conducted using the automated 
system (Fig. 4A and Table 2 in I). As compound libraries were stored in DMSO, 
a DMSO tolerance test of the assay was performed. The assay showed tolerance 
up to 2 % of the DMSO in case of TNKS1 and up to 3 % in case of TNKS2 
without any significant effect on the enzyme activity, making it appropriate to 
test compounds even at the concentrations over 100 µM.  
4.1.4 Validatory Screening and potency measurements (I) 
A chemical library consisting of 142 natural products was screened at 10 µM 
concentration (Fig. 5A in I). Separate controls containing the compounds and 
NAD+ were used for each compound. The hit limit was set at 2 × SD from the 
controls and nine hit compounds were identified. Five of them were found to be 
flavone derivatives (apigenin, luteolin, myricetin, alpha-napthoflavone, and 
flavone) (Fig. 5B in I). Flavone had been identified earlier also in a yeast based 
assay (Yashiroda et al, 2010). The best TNKS1 inhibitor was flavone (1 in Table 
4) followed by luteolin (3 in Table 4), apigenin (2 in Table 4) and isopropyl 
gallate. Although one more gallate, gallotannin showed inhibition, other gallates 
present in the chemical library were not able to inhibit TNKS1. A western blot 
using bioNAD+ as a substrate was also used to complement the fluorescence 
assay results. The western blot results showed that all the compounds were able 
to inhibit at 10 µM, while flavone stood out as the best inhibitor (1 in Table 4). 
Known potent tankyrase inhibitors XAV939 and IWR-1 were used as controls, 
and they completely inhibited the enzyme activity. Potency measurements were 
conducted for four most potent hits flavone, apigenin, luteolin and isopropyl 
gallate against TNKS1, ARTD1 and ARTD2. Luteolin (3 in Table 4) did not 
show selectivity towards tankyrases, while others were found to be selective 
towards TNKS1.  
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4.2 Identifications of flavones as potent and selective 
tankyrase inhibitors (III, IV) 
Flavones were found to be the best tankyrase inhibitors during the validatory 
screening using natural product library (Narwal et al, 2012a). Flavone was the 
most potent hit in the screened natural product library and other flavones such as 
apigenin and luteolin were not very potent, but still showed selectivity towards 
tankyrases over ARTD1. This suggested that flavonoids could contain novel 
scaffolds selectively inhibiting tankyrases.  
4.2.1 Screening of the flavonoids library and binding mode of 
flavones (III) 
Flavonoids contain a benzene ring condensed with a pyran or pyrone ring which 
is further attached to a phenyl group. A nature-inspired flavonoid library 
containing 500 compounds was screened using TNKS2 catalytic domain. 
Compound library was screened in duplicates at 1 µM concentration and the hit 
limit was set to 60 % activity in order to identify compounds of equal or better 
potency compared to the base compound flavone (1 in Table 4). Ten compounds 
displayed inhibition against TNKS2, and were re-tested to confirm the results. 
Finally, seven compounds were identified as inhibitors. Interestingly, all the hits 
contained the common flavone scaffold. Inhibitor potencies were measured for 
TNKS1, TNKS2 and ARTD1. Results (Table 4) showed that IC50-values were in 
the range of 0.047 µM – 3.1 µM for TNKS1. Compound 2 despite of having 
potency value in µM range showed selectivity (33-folds) towards tankyrases 
compared to ARTD1. In addition, compound 5 displayed even higher selectivity 
(over 200-folds) towards tankyrases (Table 4).  
The crystal structure of TNKS2 in complex with flavone (1 in Table 4) showed 
that it binds to the nicotinamide site of the binding cavity. The oxygen of the 
benzopyran-4-one forms hydrogen bonds with the main chain amide of Gly1032 
and hydroxyl of Ser1068. The pyran ring of flavone forms π-π interactions with 
Tyr1071. In contrast to other typical ARTD inhibitors, flavone contains a carbon 
at position 3 instead of amide, which was situated at a hydrogen bond distance 
from the main chain carbonyl of Gly1032.  
The above mentioned interactions were shared by most of the flavone derivatives 
with some exceptions. Compound 2 (4´, 5, 7-trihydroxyflavone) (IC50 = 3.1 µM) 
and 3 (3´,4´,5,7-tetrahydroxyflavone) (IC50 = 2.4 µM) (Table 4) had additional 
hydroxyl groups attached to the flavone scaffold. The hydroxyl at position 5 
formed a nonoptimal hydrogen bond with the Ser1068 hydroxyl. However, the 4- 
hydroxyl was pushed further away, and did not make any interaction with 
Ser1068. The co-crystal structures of TNKS2 in complex with 2 and 3 revealed 
that Ser1068 exhibited two conformations. Other hydroxyl groups made 
hydrogen bonds with the protein and water molecules (Fig. 5b,c in III). The 
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hydroxyl at position 7 in compounds 2; 3; 4 (3´,7-dihydroxyflavone) (IC50 = 0.28 
µM); 5 (7-hydroxy, 4´-methoxyflavone); (IC50 = 0.56 µM); and 6 (3´,4´, 7-
trihydroxyflavone) (IC50 = 0.63 µM); formed hydrogen bonds with the catalytic 
Glu1138 via their 7-hydroxyl group (Fig. 5a-f in III) (Table 4). 
The compounds containing 3´-hydroxyl group such as 4, 6, 7 (3´-
hydroxyflavone) and 8 (3´,4´- dihydroxyflavone) (Table 4) were hydrogen 
bonded to water molecule connecting the compound with the His1031 and 
Ser1033. Compounds 5, 9 and 10 contained methoxy, fluorine and a methyl 
substituent, respectively at position 4´ (Table 4). These substituents mostly 
formed the hydrophobic interactions with Pro1034 and Phe1035. Notably, these 
three compounds were also selective toward TNKS1 over TNKS2.    
Table 4. Chemical structure of Flavones inhibiting tankyrases. IC50-values are indicated 
against TNKS1, TNKS2 and ARTD1. 
 Structure IC50  Structure IC50 
1 
 
TNKS1 330 nM 
TNKS2 140 nM 
ARTD1 1.4 µM 
6 
 
TNKS1 630 nM 
TNKS2 870 nM 
ARTD1 7.5 µM  
2 
 
TNKS1 3.1 µM 
TNKS2 2.9 µM 
ARTD1 ~100 µM   
7 
 
TNKS1 310 nM  
TNKS2 310 nM 
ARTD1 2.4 µM 
3 
 
TNKS1 2.4 µM 
TNKS2 1.1 µM 
ARTD1 4.2 µM 
8 
 
TNKS1 230 nM 
TNKS2 170 nM 
ARTD1 1.3 µM 
4 
 
TNKS1 280 nM 
TNKS2 620 nM 
ARTD1 9.5 µM 
9 
 
TNKS1 280 nM 
TNKS2 1.1 µM 
ARTD1 9.9 µM 
5 
 
TNKS1 560 nM 
TNKS2 450 nM 
ARTD1 >100 µM 
10 
 
TNKS1 47 nM 
TNKS2 1.1 µM 
ARTD1 25 µM 
4.2.2 Screening of the flavones with single substitutions and co-
crystal structures (IV) 
Based on the aforementioned results, we decided to screen commercially 
available flavones with single substitutions to identify the features required for 
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the potency and selectivity (Table 5a, 5b). This screening was performed using 
TNKS1 and complex crystal structures with the potent compounds were solved 
using TNKS2 catalytic domain. Biochemical assay results showed that the 
substitutions to other than 4´-position, abolished the compound inhibitory activity 
in most of the cases with some exceptions (Table 5a). Co-crystal structures of 
TNKS2 were solved in complex with potent inhibitors. The structures were 
solved at 1.7 Å - 2.3 Å resolution (Supplementary Table 1 in IV). The crystal 
structures explained the potency values of the compounds. Introduction of 
hydrophobic or halogen atoms to position 3 abolished the activity of the 
compounds (Table 5a). Analysis of crystal structures showed that compounds 2-5 
containing substitutions at position 3 cannot inhibit because there is no space to 
accommodate the substitution and the compounds would clash with Gly1032 
(Fig. 4. in IV). Similarly introducing the substituents to position 7 (compounds 
6-8) (Table 5a) would lead to clashing with the catalytic Glu1138. Compounds 
11 and 12 contained methoxy and methyl groups to position 6. These groups will 
again clash with the catalytic Glu1138 and also with the main chain of Phe1061. 
Likewise, introducing the methoxy group (compound 13) to position 2´ or 6´ 
(Table 5a) would cause clashes with the side chain of His1031 and with Gly1032 
or Tyr1050. These compounds were not able to inhibit even at 10 µM 
concentration. Halogen substitutions to position 6 such as in compounds 9 and 10 
were tolerated and the potencies (9, IC50 = 210 nM and 10, IC50 = 595 nM) (Table 
5a) were comparable to the base compound. 
Compound 9 contained the fluorine atom at position 6, this fluorine didn’t form 
any hydrogen bonds, and the compound had the same interaction as the base 
compound 1. However, fluorine was close to the hydrophobic parts of the side 
chains of Glu1138, Lys1067, Ala1064 and Phe1061. The analysis of complex 
crystal structure showed that there was enough space to accommodate this 
substitution (Fig. 4b in IV) and that is why compound 9 was able to inhibit 
tankyrases. 
Compound 10 (Fig. 4c in IV) contained chlorine in position 6, and the larger size 
of chlorine might be reason for its lower potency compared to compound 9. 
Introduction of hydrophobic groups to position 6 led to only weak inhibition. The 
substitution of dioxolane ring fused with phenyl group in compound 14 at 
position 3´ and 4´ was well tolerated, and has an IC50-value of 360 nM 
comparable to flavone (Table 5a). This modification was tolerated as there is 
space in the binding cavity to accommodate this (Fig. 4d in IV).  
In contrast, modifications to position 4´ improved the potency, and in some of the 
cases also led to the better selectivity in comparison to the base compound 
(Table 5b). The substitutions of halogens (compounds 15-17) (Table 5b) 
resulted in variable potency (15, IC50 = 700 nM; 16, IC50 = 233 nM; 17, IC50 = 
313 nM) depending on their sizes and their interactions with the neighboring 
hydrophobic residues Pro1034 and Phe1035 (Fig. 5a,b,c in IV). However, there 
was no improvement in the potency compared to 1. 
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Table 5a. Evaluation of flavone derivatives as tankyrase inhibitors. IC50-values were 
measured for 1, 9, 10 and 14 against TNKS1 
 Structure IC50   Structure IC50 
1 
 
330 nM 
 
 
8 
 
>10 µM  
2 
 
>10 µM 
 
9 
 
210 nM  
 
3 
 
>10 µM 
 
10 
 
595 nM 
 
4 
 
>10 µM 
 
11 
 
>10 µM 
5 
 
>10 µM 
 
12 
 
>10 µM 
6 
 
~5 µM 
 
13 
 
>10 µM 
7 
 
>10 µM 
 
14 
 
360 nM 
 
 
Compounds 18 (IC50 = 788 nM) and 19 (IC50 = 850 nM) contained a hydroxyl 
group and a carboxyl group, respectively. These compounds were not potent, 
because they were surrounded by the hydrophobic residues Pro1034 and Phe1035 
and had non-favorable interactions (Fig. 5d,e in IV). However, introduction of 
nitro group (compound 20) improved the potency (IC50 = 66 nM) by forming the 
hydrogen bonds with Ala1049 and Ile1051 through one bridged water molecule 
(Fig. 5f. in IV). Compounds 21 (methyl) and 22 (isopropyl) (Fig. 8) improved 
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the potency a lot with the IC50-values of 47 nM and 6 nM (Table 5b). This 
improvement was because of their efficient hydrophobic interactions with 
Pro1034 and Phe1035 (Fig. 5g,h in IV).  
Table 5b. Evaluation of flavone derivatives as tankyrase inhibitors. IC50-values are shown 
against TNKS1 
 Structure IC50   Structure IC50 
15 
 
700 nM 
 
 
23 
 
67 nM  
16 
 
233 nM 
 
24 
 
71 nM  
 
17 
 
313 nM 
 
25 
 
272 nM 
 
18 
 
788 nM 
 
26 
 
162 nM 
19 
 
850 nM 
 
27 
 
146 nM 
20 
 
66 nM 
 
28 
 
145 nM 
21 
 
47 nM 
 
29 
 
7 nM 
 
22 
 
6 nM 
 
30 
 
114 nM 
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Figure 7. IC50-value measurement of the compounds 21 and 22 for TNKS1. Log of molar 
concentration of inhibitor (log M) is plotted on x-axis and conversion % is plotted on y-
axis. Standard deviation is shown for each point. Curves were fitted with Graphpad Prism 
using sigmoidal dose response curve and four variables.   
Dimethyl amine substitution in 23 showed improvement in the potency (IC50 = 67 
nM) compared to the base compound 1. This was because of the additional 
hydrogen bonding with the water network (Fig. 5i in IV). Compound 24, 
carrying a methoxy group, (IC50 = 71 nM) (Fig. 5j in IV) displayed improvement 
in selectivity due to hydrophobic interactions similar to 21 and 22.    
Substituting the 4´-position with ethyl methanoate (25, IC50 = 271 nM) and 
methyl methanoate (26, IC50 = 162 nM) had similar hydrophobic interactions and 
hydrogen bonds with the protein molecule (Table 5b) (Fig. 5k,l in IV). The co-
crystal structure of TNKS2 in complex with compound 27 (methylpiperazine-1-
carbonyl) (IC50 = 146 nM) showed that the D-loop was moved to accommodate 
the inhibitor. The core of the compound was rotated approximately 5º towards 
Tyr1071. The residues 1046-1051 lining the D-loop were moved approximately 
0.9 Å in order to accommodate the large substituent. This movement has 
loosened the packing between the D-loop residues and active site helix 1059-
1062, and also His1048 was rotated disrupting the hydrogen bond betwee+n 
His1048 and Asp1045 (Fig. 5m in IV). 
Compound 28 (Table 5b) contained a cyano group and in spite of having a better 
potency (IC50 = 145 nM) compared to the base compound, it didn’t make any 
additional interactions with the protein molecule (Fig. 5n in IV). In contrast to 
the other compounds, 29 containing the cyanomethyl acetate substituent was the 
only inhibitor that formed the direct hydrogen bond with the protein molecule 
(Fig. 5o in IV). This additional hydrogen bond accounted for the very low IC50-
value of 7 nM of this compound. Compound 30 (Table 5b) had a tetrazol 
substitution and it formed an additional hydrogen bond with a water molecule 
(Fig. 5p in IV) and displayed an IC50-value of 114 nM (Table 5b).  
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Figure 8. Binding mode of compound 22 (in yellow) with TNKS2 catalytic domain (in 
blue). Hydrogen bonds between the compound and protein molecule residues are 
presented as black dashed line.   
4.2.3 Inhibition of Wnt signaling and profiling of the inhibitors (IV)  
The compounds with an IC50-value cut-off of 200 nM were further tested in a 
cell-based assay using SuperTopFlash (STF) TCF-reporter plasmid (Fig. 1 in 
IV). Ten compounds were tested at three different concentrations. Seven 
compounds showed inhibition at 5 µM, but at 200 nM only compound 22 showed 
inhibition. (Fig. 1 in IV). Thus, the efficacy of 22 in cell-based assay and also in 
biochemical assay made it the best inhibitor in the library tested.  
To determine the selectivity of the hit compounds, they were profiled against a 
panel of ARTD superfamily members (Fig. 2 in IV). Results revealed that most 
of the compounds did not inhibit other ARTD enzymes at 1 µM concentration. 
Compound 22 was the most potent and also the most selective compound, as it 
displayed very low potency for other isoenzymes. Selectivity of the best 
compounds was confirmed by measuring the IC50-values against ARTD1 (22, 
IC50 = 19.1 µM), ARTD2 (22, IC50 = 34.9 µM), TNKS1 (22, IC50 = 6 nM) and 
TNKS2 (22, IC50 = 72 nM) using the biochemical assay, and XAV939 was used 
as a control compound (Table 3 in IV). Analysis of the potency values showed 
that 22 was the most potent and selective compound. Compound 22 improved the 
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selectivity in comparison to XAV939 and also maintained the single digit 
nanomolar potency against TNKS1.  
4.3 Inhibitor binding to adenosine site (II) 
4.3.1 Co-crystal structure of TNKS2 catalytic domain in complex 
with IWR-1  
The co-crystal structure of TNKS2 containing IWR-1 (Fig. 3c in II) was 
determined using protein X-ray crystallography. Unlike all other known ARTD 
inhibitors at that time, IWR-1 (Fig. 6) did not utilize the traditional nicotinamide 
binding site and was rather bound to the adenosine site (Fig. 3c in II). The solved 
crystal structure showed that the compound induced movement of the D-loop, 
which otherwise is in the closed conformation in the apo structure. Chemically 
IWR-1 structure could be divided into three parts: amide, spacer and norbornyl 
region (Fig. 6). The carbonyl oxygen of the amide region formed hydrogen bond 
with the amide of the Asp1045. Amide region in the inhibitor contained a 
quinolone moiety that was situated between the hydrophobic face of the helix 
1035-1042 and His 1048, that would have clashed with the amide region if not 
moved out of the cavity.  
Spacer region of IWR-1 was present in between the reorganized D-loop and in 
the vicinity of hydrophobic region formed by His1031, Phe1044 and Ile1059. 
The carbonyl oxygens of the norbornyl region formed two hydrogen bonds with 
the backbone amides of Tyr1050 and Tyr1060. The norbornyl region was located 
in the middle of three tyrosines (Tyr1050, Tyr1060 and Tyr1071) and had 
nonpolar interactions with them (Fig. 3c in II). All of the tyrosines adopted a 
different conformation in comparison to other known crystal structures. The 
Tyr1050 was moved 5 Å away from the cleft and formed nonpolar interactions 
with IWR-1 and Ile1075. The Tyr1060 side chain was moved 1 Å towards IWR-
1. Tyr1071 showed a rotation of 51º in order to interact with the compound and 
this closed the nicotinamide-binding site. The catalytic Glu1138 also adopted a 
slightly different conformation in comparison to nicotinamide bound structure 
(Fig. 3c in II).    
4.3.2 Structure-activity relationship studies of IWR-1 analogues 
Prior to this contribution, a structure-activity relationship study of IWR 
analogues using the cell based assays was published (Lu et al, 2009). In that 
study, it was suggested that all three regions of the compound are important for 
potency. At that time the molecular target of IWR-1 (Fig. 6) was unknown and 
now with the help of TNKS2-IWR-1 complex crystal structure, some of the 
effects in the cells could be explained. In the crystal structure, the movement of 
His1048 and rotation of Phe1035 led to the formation of a new cavity which is 
occupied by the quinoline moiety of the amide region (Fig. 5a in II). Quinoline 
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ring was very critical for the potency and substitution of quinoline ring with 
smaller aromatic groups such as phenyl, benzyl, and pyridyl groups have led to 
almost complete loss of activity (EC50 > 20 µM). However, the phenyl 
derivatives with halogen substitution at position 4 (EC50 ~ 2.6 µM) and 4- 
pyridyl-methyl derivatives (EC50 = 10 µM) improved the potency. These 
substitutions might form favorable interactions with Lys1042 and direct the 
compound to bind tightly to the protein molecule (Fig. 3c in II). Trans-(2-
methoxy) cyclohexyl and 2-methoxyphenyl analogues showed improved potency 
of 2 µM and 1 µM respectively. This might be because of their hydrophobic 
interactions with the α-helix 1035-1042 (Fig. 4 in II). Notably, N-methyl 
derivatives were inactive because they would not allow the conformation of the 
compound observed in the crystal structure. 
Spacer region forms hydrophobic interactions with the side chains of the protein 
molecule (Fig. 3c in II).  The length of the spacer region was found to be more 
critical in comparison to its aromaticity. The addition of just one atom inactivated 
the compound completely, and saturated analogue showed reasonable potency 
(0.2 µM). Small substitutions to position 3 (Fig. 6) in the spacer region were 
tolerated because of the flexibility of D-loop. However, substituents at position 2 
(Fig. 6) completely abolished the activity. Saturation of norbornyl region did not 
affect the potency of the inhibitor, while exo-IWR-1 (exo-isomer of the 
compound) was less potent and was effective only at higher concentration. This 
might be because exo-IWR-1 is less complementary to the binding site.  
4.3.3 IWR-1 selectivity 
IWR-1 was identified as a very selective tankyrase inhibitor. It has IC50-values of 
131 nM and 56 nM for TNKS1 and TNKS2, respectively, compared to an 
approximate IC50-value of more than 18.7 µM for ARTD1 and ARDT2 (Huang 
et al, 2009). To confirm the results we measured the effect of IWR-1 on ARTD1 
and ARTD2, and the results showed that IC50-value for ARTD1 and ARTD2 
would be 100 µM and 35 µM, respectively. Therefore, IWR-1 was 600-fold 
selective towards tankyrases compared to ARTD1 and ARTD2. These results 
were verified in another contribution (Haikarainen et al, 2013a). Superposing the 
ARTD1 crystal structure on the TNKS2-IWR-1 structure elucidated the features 
that could explain the IWR-1 selectivity (Fig. 5b in II). In the TNKS2 complex 
structure with IWR-1, Tyr1060 and Asp1045 of TNKS2 formed hydrogen bonds 
with the compound. In case of ARTD1, these amino acids are replaced by 
Tyr896 and Asp766. Asp766 could form a hydrogen bond with the carbonyl of 
the norbornyl region, if it is protonated. The norbornyl of the compound was 
surrounded by three tyrosines in TNKS2, whereas in ARTD1 only two of them 
(Tyr889 as Tyr1050 and Tyr896 as Tyr1060) were conserved. Furthermore, 
Ile1075 and zinc binding motif are absent in ARTD1, and Ile1075 is replaced by 
a negatively charged chain of Gln763 of regulatory domain at this position. 
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Major differences between TNKS2 and ARTD1 were noticed at the quinoline-
binding site. The hydrophobic residues Phe1035 and Phe1044 are not conserved 
in ARTD1, and Phe1035 is completely absent. In ARTD1, binding site is 
surrounded by more polar amino acids compared to TNKS2. The quinoline of 
IWR-1 would clash with the salt bridge formed by Arg878 and Asp770 of 
ARTD1 regulatory domain. Also, the stacking interaction of His1048 with 
quinoline is not conserved in ARTD1 (Fig. 5b in II). The structural differences 
between the catalytic domains of TNKS2 and ARTD1 along with the novel 
features of IWR-1 made it a good compound for further development as a 
selective tankyrase inhibitor. 
4.4 Characterization of known ARTD inhibitors (V) 
In order to evaluate known ARTD inhibitors as tankyrase inhibitors, they were 
screened against TNKS1 using fluorescence-based activity assay and potencies 
were measured for the hit compounds. Finally, co-crystal structures were solved 
using protein X-ray crystallography and structure-activity relationship was 
established.  
4.4.1 Screening of the inhibitors and potency measurements 
Screening of the known ARTD inhibitors was conducted at 10 µM concentration 
and 14 compounds out of 32 showed more than 50 % inhibition (Fig. 1 in V). In 
order to confirm the results and to identify the most potent hits, the small 
chemical library was re-screened at 500 nM. Nine compounds still displayed 
more than 20 % inhibition and these compounds were chosen for further 
characterization. All of the hits, except IWR-1, contained the nicotinamide motif. 
Five of these compounds were already reported as tankyrase inhibitors and had 
been characterized with protein X-ray crystallography, these compounds 
included 17 (PJ-34; TNKS1, IC50 = 570 nM) (Kirby et al, 2012; Wahlberg et al, 
2012), 21 (Olaparib; TNKS1, IC50 = 1500 nM) (Menear et al, 2008; Narwal et al, 
2012b), 23 (XAV939; TNKS1, IC50 = 11 nM) (Huang et al, 2009; Karlberg et al, 
2010), 26 (IWR-1; TNKS1, IC50 = 130 nM) (Narwal et al, 2012b), and 32 
(flavone; IC50  = 330 nM) (Narwal et al, 2013a, 2012a; Yashiroda et al, 2010).  
Therefore, the binding mode of additional four compounds was studied using 
protein X-ray crystallography. These compounds were 10 (EB-47) (Jagtap et al, 
2004), 16 (Phenanthridinone) (Banasik et al, 1992), 18 (TIQ-A) (Chiarugi et al, 
2003), and 29 (Rucaparib) (Thomas et al, 2007) (Fig. 9). In a previously reported 
structure, PJ-34 was bound to both the sites in binding cavity; therefore, PJ-34 
was also selected for the structural studies. PJ-34 (Compound 17) is also a 
phenanthridinone and TIQ-A (Compound 18) structure is also similar to 
compound 16 and 17 with three aromatic rings fused together (Fig. 9). Rucaparib 
contains three rings with one seven membered non-aromatic ring, and also had a 
large (methylaminomethyl) phenyl substituent. EB-47 was designed to mimic 
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NAD+; it has a nicotinamide part attached to the adenosine part with a linker 
replacing the ribose-diphosphate (Fig. 9).   
 
 
Figure 9. Chemical structures of the hit compounds; EB-47 (10), Phenathridinone (16), 
PJ-34 (17), TIQ-A (18), and Rucaparib (29) are presented. IC50-values are indicated for 
TNKS1 and TNKS2 
Compounds 16 and 18 displayed IC50-values of 110 and 200 nM, respectively. 
Though, 17, which is a derivative of 16 showed lower potency of 1300 nM. 10 
showed a potency of 410 nM. 29 emerged as the best scaffold for inhibiting 
TNKS1 among hits with an IC50-value of 25 nM (Fig. 9). However, 10 and 29, 
both displayed selectivity towards ARTD1 over TNKS1 (Table 1 in V). The 
potencies of these five compounds were also measured with ARTD1 and 
TNKS2. Surprisingly, these compounds were selective towards TNKS2 over 
TNKS1 (Fig. 9).  
4.4.2 Binding modes of the compounds  
Binding mode of 10 (EB-47) will be discussed in detail in the section 4.5. Other 
compounds will be discussed here. 
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4.4.2.1 Binding modes of Phenanthridinone (16) and TIQ-A (18)  
16 and 18 (Fig. 9) make known interactions with the protein molecule (Fig. 2a,b 
in V). They formed hydrogen bonds with Gly1032 and Ser1068 and the 
characteristic π-π interactions with Tyr1071. These inhibitors form hydrophobic 
interactions with Tyr1060 and Lys1067, and aromatic C-ring also have 
hydrophobic interactions with Tyr1050 and Ile1075. Both of the co-crystal 
structures were very similar and the difference in potency might come from 
better interactions of the six membered ring of the 16 (Fig. 9) Tyr1050 and 
Ile1075 are not conserved in ARTD1 that could explain slight selectivity towards 
TNKS1 over ARTD1. 
4.4.2.2 Binding mode of PJ-34 (17) 
Binding mode of 17 was very similar to the binding modes of 16 and 18 (Fig. 2c 
in V). The compounds made all the characteristic interactions of general ARTD 
inhibitors. However, the presence of long dimethylamino acetamide tail in PJ-34 
(17) caused the opening of the D-loop in the co-crystal structure as otherwise the 
tail would have clashed with the Tyr1050. The D-loop was opened up and it did 
not make any stable interactions with the compound. In addition, the tail of the 
compound avoids contact with Tyr1050, and also had poor electron density in the 
crystal structure (Fig. 2c in V). Tyr1060 also rotated approximately 15 degrees 
towards the compound compared to the TNKS2-16 co-crystal structure. The 
hydrogen bond length of the amide of 17 with the carbonyl of Gly1032 was 2.9 Å 
(compared to 2.7 Å in both 16 and 18 structures). Previously, a complex crystal 
structure of TNKS2 was reported with 17 that had two molecules of the 
compound binding to the protein molecule (Kirby et al, 2012). In contrary, we 
observed only one molecule binding to the nicotinamide site.     
4.4.2.3 Binding mode of Rucaparib (29) 
Compound 29 is a large inhibitor and possesses a molecular weight of 323 Da (Fig. 
9). It is an optimized ARTD1 inhibitor containing a nicotinamide-like motif fused 
with a seven membered B-ring (Fig. 1 in V). 29 also forms known interactions at 
the nicotinamide site. Like 17, the hydrogen bond distance with the Gly1032 was 
2.9 Å. The fluorine atom of the compound was interacting with the hydrophobic 
regions of the catalytic Glu1138 and Ala1068 (Fig. 2d in V). The amide of the D-
ring forms a hydrogen bond with the water molecule which is further interacting 
with a network of water molecules. Like the tail of 17, (methylaminomethyl) 
phenyl substituent also extends from the nicotinamide site and causes changes in 
the active site. D-loop opened up and was completely disordered in the crystal 
structure (Fig. 2d in V). Large phenyl group also caused changes in the structure 
by rotating Tyr1060 and Tyr1071 15 degrees and 30 degrees, respectively. This 
rotation made Tyr1071 parallel to the aromatic D-ring. In addition, phenyl group 
also changed the conformation of Ile1075 (Fig. 2d in V).         
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Although, binding of 29 also disordered the D-loop, the additional interactions 
made by 29 with its tricyclic core and efficient stacking with the hydrophobic 
residues at the active site made it highly potent TNKS inhibitor. 
4.5 Substrate Binding (II, V) 
There is no substrate bound structure available; therefore, we soaked NAD+ and 
one NAD+ mimic compound (EB-47) in order to understand the molecular 
interactions between the substrate and TNKS2 catalytic domain. 
4.5.1 Co-crystal structure of TNKS2 catalytic domain in complex 
with nicotinamide (II) 
In order to solve the NAD+ bound crystal structure, TNKS2 crystals were soaked 
in high concentrations (10 mM) of the substrate. However, only nicotinamide 
was found to be bound to the TNKS2 protein crystals instead of NAD+. 
Nicotinamide, as expected, was binding to the nicotinamide site in the crystal 
structure. The carboxamide was hydrogen bonded to the Gly1032 and Ser1068, 
and nicotinamide also had π-π interactions with Tyr1071 (Fig. 2a in II). The 
stacking is not efficient because aromatic ring was situated at an angle of 39 
degrees with respect to the plane of Tyr1071. In addition, nicotinamide formed 
hydrogen bonds with the water molecules present next to the conserved HYE 
triad made by His1031, Tyr1071 and Glu1138 (Fig. 2a in II). The TNKS2 
protein used in the structure determination was treated with chymotrypsin, 
therefore this result showed that even chymotrypsin cleaved protein could 
catalyze automodification reaction and it was also verified with western blot 
(Fig. 2b in II). 
4.5.2 Co-crystal structure of TNKS2 catalytic domain in complex 
with EB-47 (V) 
EB-47 (10) is a known ARTD1 inhibitor that was designed to mimic the ARTDs 
substrate NAD+ (Jagtap et al, 2004). The chemical structure of 10 consists of a 
nicotinamide region attached to the adenosine moiety with a linker replacing 
ribose-diphosphate (Fig. 10a). In the crystal structure, 10 binds to the NAD+ 
binding channel, and extends from the nicotinamide binding site to the adenosine 
binding site. Isoindolinone moiety of the inhibitor bound to the nicotinamide site 
and formed hydrogen bonds with the Gly1032 and Ser1068 (Fig. 10a). 
Compound binding caused the opening of the D-loop, and unlike in the 17 and 29 
co-crystal structures, the loop was visible in the crystal structure. Tyr1050 was 
moved out of the binding cavity. Carbonyl of the linker interacted with the 
backbone of Tyr1060 through water molecules (Fig. 10a). Other interactions 
made by linkers are hydrophobic in nature. Hydroxyls from the ribose moiety 
formed hydrogen bonds with His1031 and Ser1033.  
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Figure 10. Stereo view of binding mode of compound 10 with TNKS2 and its 
comparison with NAD+ bound diphtheria toxin crystal structure. (a) TNKS2 (blue 
colored) in complex with 10 (light grey); (b) comparison of superposed 10 with NAD+ in 
diphtheria toxin; (c) NAD+ bound diphtheria toxin  (PDB code: 1TOX)  
Notably, these amino acid residues are conserved in other members of ARTD 
enzyme superfamily. Furthermore, the adenosine moiety was situated between an 
α-helix and His1048 and it formed hydrogen bonds with the backbone atoms of 
Gly1043 and Asp1045 (Fig. 10a) 
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The comparison between 10 in complex with the TNKS2 catalytic domain and 
NAD+ bound diphtheria toxin crystal structure (PDB code: 1TOX) (Bell & 
Eisenberg, 1997) showed that the overall binding mode of 10 is very similar to 
NAD+ (Fig. 10c). Both NAD+ and 10 did not make any interactions with the D-
loop. In the co-crystal structure containing 10, the adenosine moiety was rotated 
180º in comparison to the ARTD1-NAD+ complex structure (Fig. 10c).   
In diphtheria toxin crystals, the adenosine region of the NAD+ was hydrogen 
bonded to conserved amino acid residues His21 and Thr23, and also to a water 
molecule. Adenosine moiety also formed hydrogen bonds with Gly34 and Gln36 
(Fig. 10c). The histidine, unique to tankyrases, that was stacking with 10 in the 
complex crystal structure, was also missing in the diphtheria toxin structure. 
These differences may therefore indicate that the binding mode in human ARTDs 
or in tankyrases could be distinct from the diphtheria toxin or the rotation could 
be just a property of the inhibitor.  
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5 Discussion 
TNKS1 was first discovered 15 years ago and since then tankyrases have been 
implicated in many cellular processes (Smith et al, 1998). Their functions such as 
involvement in the telomere homeostasis and in the Wnt signaling have made 
them very interesting drug targets. Just after this PhD project was started, it was 
suggested that TNKS1 inhibition suppress the oncogenic Wnt signaling (Huang 
et al, 2009) and this directed many research groups to develop selective 
tankyrase inhibitors. At that moment, the field was very new and there was very 
little known about the possible small molecules that could inhibit tankyrases 
selectively. During this PhD project the field has grown tremendously and many 
research groups including ours have reported potent tankyrase inhibitors.  
5.1 The screening assay (I, III, IV) 
The first step towards the discovery of inhibitors was the development of an 
assay that could be used for screening the chemical libraries. There were some 
tankyrase assays available earlier, but it was difficult to evaluate the usefulness 
and robustness of those assays for screening. We adapted the assay developed for 
ARTD1 (Putt & Hergenrother, 2004) and optimized it for tankyrases. The assay 
was based on the automodification activity of enzymes, which means that 
tankyrases will act both as the enzyme and the target protein. The chemical 
reaction is based on the principle that N-alkylpyridinium compounds can be 
converted to fluorescent product through reaction with a ketone followed by 
heating in excess acid. All the chemical screening and potency measurements 
were performed at pH 7 because of its closeness to the physiological pH. 
Traditional PARP/ARTD phosphate buffer, pH 8, containing Mg2+ (Putt & 
Hergenrother, 2004) was not a good choice for TNKS1 activity. As TNKS1 was 
less active at pH 8 and Mg2+ was also inhibiting the enzyme activity. Different 
buffers and reagents were tested for enzyme activity and finally the most suitable 
of them was used depending upon the different constructs. 
Assay performance was analyzed manually and with a pipetting robot. Signals 
were normally distributed and statistics showed that assay is robust for screening 
compounds. Incubation times were adjusted to achieve the high performance of 
the assay. It was observed that even with the manual setup, it was possible to 
screen hundreds or thousands of compounds per day. Assay was carried out using 
very low substrate concentration that made it sensitive to the competitive 
inhibitors. 
There have been some ARTD assay reports earlier but they required special 
reagents such as colorimetric modification of the substrate NAD+, bioNAD+, or 
radiolabeled NAD+ (Nottbohm et al, 2007; Schraufstatter et al, 1986; Zhang & 
Snyder, 1993). In comparison, the assay used here is very inexpensive and does 
not require any washing steps. In addition, it is possible to use the protein 
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purified using E. coli as host organism even with a single purification step 
without the need of any special kit. Previously, only two screening assays had 
been described for TNKS1. They were based on a colorimetric substrate variant 
and yeast cell-based screening method (Nottbohm et al, 2007; Yashiroda et al, 
2010). In the colorimetric assay, the measurement could be done at any point, but 
the signal observed appears not to be as robust as with the fluorescence method. 
In the yeast based system, the yeast strains were used to overexpress TNKS1 and 
compounds were screened that can protect the cells against the TNKS1-induced 
growth arrest. Being a whole cell-based assay, there is possibility of detecting the 
nonspecific hits that can protect the cells by other mechanisms. In contrast to 
other assays, the biochemical assay used is high throughput, feasible, simple, has 
high DMSO tolerance, is compatible with the automatic system, and of low cost. 
This assay has also been successfully optimized for other ARTD members in our 
laboratory. Best buffers were selected depending on the enzymatic activity of 
ARTD members. In case of ARTD1 and ARTD2, activated DNA was added to 
the final buffer, whereas, an additional substrate protein was used with some 
mono ARTDs such as ARTD7 and ARTD10 (Haikarainen et al, 2013a, 2013b; 
Narwal et al, 2013b; Venkannagari et al, 2013). 
A validatory screening was done in order to check the assay performance and 
results were confirmed with western blot. Hit limit was set to 2 × SD to get more 
hit compounds in the initial stage of the screening and three of the hit compounds 
showed selectivity towards TNKS1 over ARTD1 and ARTD2. The potency 
value of flavone was measured with TNKS1 using the biochemical assay and the 
IC50-value of 325 nM agreed well with the previous studies in yeast cell lysates 
(Yashiroda et al, 2010). In addition we measured potencies of the known potent 
tankyrase inhibitors XAV939 (IC50 = 5 nM) and IWR-1 (IC50 = 64 nM) against 
TNKS1, which were in accordance with the previously reported values (Huang et 
al, 2009).  
5.2 Flavones as tankyrase inhibitors (III, IV) 
Flavone has been identified as a TNKS1 inhibitor in a yeast-based screening 
method and also in our validatory screening using the natural compound library 
(Narwal et al, 2012a; Yashiroda et al, 2010). This raised the question, whether 
other classes of flavonoids would also be able to inhibit tankyrases. Flavonoids 
are secondary metabolites that are widely present in plant sources and in our 
daily diet (Aron & Kennedy, 2008; Benavente-García et al, 1997; Landete, 
2012). They are further divided into various classes such as flavones, isoflavones, 
flavonones, anthocyanidines, flavanols, and flavonols (Harborne & Williams, 
2000). It has been suggested that flavonoids have several beneficial properties 
such as antioxidant, neuroprotective, antiviral, and anticancer properties (Birt et 
al, 2001; Galati et al, 2000; Middleton et al, 2000; Yang et al, 2001). Flavonoids 
are also shown to have antiproliferative effects on several tumor cell lines 
(Kandaswami et al, 2005).  
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After discovering flavones as tankyrase inhibitors with selectivity over ARTD1, 
we decided to screen flavonoids against tankyrases (Narwal et al, 2013a) and a 
flavonoid library containing the 500 nature-inspired compounds was screened 
using TNKS2 catalytic domain. Screening results showed that flavones were the 
best inhibitors of TNKS2 among flavonoids and other classes did not inhibit 
TNKS2 at the tested concentration. 
Flavones do not contain the characteristic nicotinamide motif. They lack the 
amide, which was thought to be required for efficient binding with the 
nicotinamide site of the enzyme. There was no crystal structure available before 
this project that could explain the binding of flavones. We solved the crystal 
structure of TNKS2 in complex with flavone (Fig. 5a in III) that showed that it 
binds to the same binding pocket as do most of the ARTD inhibitors. The 
interaction between the flavone carbon at position 3 and the carbonyl of the 
Gly1032 was the result of the partial charge distribution character of the 
hydrogen and C3 carbon (Fig. 5a in III). Most of the hit compounds identified in 
the flavonoids screening contained hydroxyl groups and they did not have a high 
impact on the potency of the compounds.  
All the compounds showed similar potencies against both the tankyrases except 
for two compounds containing fluorine atom and methyl group substituted to 
position 4´ respectively, these compounds were actually selective towards 
TNKS1 over TNKS2. These differences could not be explained by the structural 
data as catalytic domains of both the tankyrases are almost identical. Our 
hypothesis was that, our TNKS1 fragment contains an additional SAM domain 
that could have improved the binding of compounds to TNKS1 by affecting the 
protein flexibility or by interacting with the binding cavity and enhancing the 
hydrophobic interactions between the compound and protein molecule. Later we 
were able to produce TNKS2 fragment containing the SAM and ARTD domains 
and we found that the presence of a SAM domain improved the potency of 
compounds by 2 to 3-fold. The SAM domain improves the enzyme activity so 
that protein was active even at very low nanomolar concentration. However, it 
does not completely explain the selectivity of inhibitors towards TNKS1 over 
TNKS2 or vice-versa.   
Flavonoids have been shown to be associated with the antiproliferative effects 
(Asensi et al, 2011; Kandaswami et al, 2005) on the cancer cells, and some of 
their effects could be because of the tankyrase inhibition. Chemical space 
analysis of the flavonoid library showed that the flavones inhibiting tankyrases 
would be small and aromatic, and generally small substitutions would be 
tolerable (Fig. 7 in III). Compounds that clustered around the hits were also 
flavones and were also inhibiting or close to the set hit limit in screening. The 
unfavorable binding of specific flavones is easily explainable with the crystal 
structure as there is no space to accommodate them in the binding cavity.  
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To get further insights about the flavones’ selectivity towards tankyrases, we 
decided to screen the commercially available flavones containing single 
substitutions. A selection criterion was to discover compounds, which would be 
more potent in comparison to base compound flavone.  Therefore, nineteen 
compounds were selected for the potency measurements on the basis of their 
inhibition at 1 µM. Co-crystal structures were also solved with all the hit 
compounds. It was observed that the position 4´ was best for substitutions (Table 
1 in IV), because it extends from the binding site towards the solvent. Position 6´ 
was also suitable for smaller substitutions but these did not improve the potency 
of the compounds. Substitution to 4´ position also led to more potent and 
selective inhibitors, as best compounds were containing hydrophobic 
substitutions to 4´ position. Compound 29 (IV) was the only compound that 
formed a direct hydrogen bond with the protein molecule. However, it did not 
show any inhibition in the cell based assay reporting the Wnt signaling 
inhibition. The potential reasons for the inactivity of the compounds could be 
nonspecific binding, cell permeability, compound solubility and stability. 
Therefore, in vitro biochemical assay and cell-based assay showed differences in 
the results.     
The complex crystal structures showed that all the compounds bind to the 
nicotinamide site as expected. As nicotinamide site is conserved in the ARTD 
enzyme family, therefore, to confirm the selectivity, IC50-values of the best 
compounds and XAV939 were measured with ARTD1, ARTD2, TNKS1 and 
TNKS2. Analysis of results showed that compound 22 (Table 5b) is more 
selective towards TNKS1 and also maintain similar potency as XAV939. 
Compound 22 (Table 5b) is most hydrophobic in the series with excellent ligand 
efficiency (Kuntz et al, 1999). 22 also maintains the lipophilic efficiency 
(Waring, 2010) at the same level as other potent compounds that were inhibiting 
Wnt signaling.  
In general, the IC50-values of the compounds were better for TNKS1 over 
TNKS2. We were expecting that larger substitutions to position 4´ might be 
better for selectivity as compounds extending in this direction would clash with 
the AH regulatory domain present in ARTD1-ARTD4, but not in ARTD5-
ARTD17 (Karlberg et al, 2010; Narwal et al, 2013a). However, this was not the 
case as the largest compound, 27 (Table 5b), showed inhibition of ARTD1 at 1 
µM concentration (Fig. 2 in IV). Our view is that some of the compounds 
possibly interacted with the highly polar binding site of ARTD1-4 (Wahlberg et 
al, 2012), and also had interaction with the AH regulatory domain present in 
these enzymes. 
Our results showed that it is possible to create selective tankyrase inhibitors 
binding to nicotinamide site. The molecular details shown by the co-crystal 
structures could be utilized in predicting and further optimizing the flavones and 
related compounds for higher potency.  
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5.3 Novel binding mode of IWR-1 (II) 
IWR-1 (Fig. 6) was identified in the STF assay as a tankyrase inhibitor. We 
solved the crystal structure of the TNKS2 in complex with IWR-1. Complex 
crystal structure showed that IWR-1 was the first compound binding to the 
adenosine site rather than to nicotinamide site (Fig. 3c in II). IWR-1 binding 
induced changes in the protein molecule at the nicotinamide-binding site, but 
most importantly it caused the opening of the D-loop. Structure-activity 
relationship analysis showed that these changes were required for the high 
potency of the compound. All three regions of the compound; amide, spacer and 
norbornyl were required and modifications of them led to lower potency or 
completely abolished the activity in Wnt signaling assay. The superposition of 
TNKS2-IWR-1 complex structure with ARTD1 showed that some of the 
interactions made by norbornyl region of the compound are conserved or 
complementary to TNKS2. However, clashes were observed between AH protein 
regulatory domain of ARTD1 and compound. This indicated that ARTD1 
domains need to open to accommodate IWR-1. The absence of required 
interactions and movement of domains in ARTD1 are major reasons behind the 
selectivity of IWR-1 towards tankrases.  
This complex crystal structure showed that targeting the adenosine site could 
lead to selective inhibition of tankyrases. The unique interaction between the 
compound and protein molecule has defined a new pharmacophore model and 
has already been used in the design of new inhibitors (Bregman et al, 2013a).  
5.4 Inhibition of tankyrases by ARTD inhibitors (V) 
A small library of ARTD inhibitors and analogues was screened against TNKS1. 
Their binding modes were studied using protein X-ray crystallography. In order 
to identify the potent tankyrase inhibitors, compounds were screened at final 
concentration of 500 nM. Nine compounds showed more than 20 % inhibition at 
this concentration, therefore, these compounds were selected further for 
characterization using a biochemical assay and crystallography. Co-crystal 
structures of TNKS2 in complex with potent tricyclic compounds 
phenanthridinone and TIQ-A (Fig. 9) showed that the inhibitors were compatible 
with the closed conformation of the D-loop and formed the hydrophobic 
interactions with the neighboring residues. These interactions are conserved in 
tankyrases and these compounds were slightly selective towards tankyrases over 
ARTD1. Screening results showed that, the clinical candidates against ARTD1, 
veliparib and iniparib displayed only 33 % inhibition and no inhibition of TNKS1 
at 10 µM, respectively. Binding of PJ-34 (17) and rucaparib (29) caused 
disordering of the D-loop. Consequently, PJ-34 displayed lower potencies 
(TNKS1 1300 nM; TNKS2 219 nM), whereas, rucaparib showed low IC50-values 
(TNKS1 25 nM; TNKS2 14 nM) (Fig. 9). Therefore, some of the effects of 
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rucaparib shown in the earlier studies as ARTD1 inhibitor could also be affected 
by tankyrase inhibition.  
5.5 Substrate binding (II, V) 
To date, there is no structural information available that could shed light on the 
molecular interactions between NAD+ and any human ARTD member. 
Therefore, in order to get further insights, we tried to soak the TNKS2 crystal 
with the solution containing high concentrations of NAD+, but soaking resulted 
in the binding of only a byproduct nicotinamide. This indicated that 
chymotrypsin cleaved enzyme used in the crystallization could hydrolyze NAD+. 
The western blot results showed that it could also catalyze covalent 
automodification reaction. However enzymatic activity was lower for the cleaved 
enzyme. Nicotinamide made the conserved interactions with the TNKS2 ARTD 
domain. The crystal structure showed that TNKS2 catalytic domain could 
accommodate inhibitors without disturbing the crystal packing and could be 
utilized in finding new inhibitors.  
EB-47 (Compound 10) (Fig. 9), NAD+ mimic compound, was soaked with 
TNKS2 crystals to evaluate ARTD inhibitors against tankyrases, and some 
indications of NAD+ binding can be deduced from the solved crystal structure. 
Superposing the NAD+ bound diphtheria toxin crystal structure (PDB code: 
1TOX) with TNKS2-10 complex structure showed that overall the conformation 
was very similar but there were differences especially at the adenosine moiety, 
which has been rotated by 180 degrees in the EB-47. Interestingly, neither NAD+ 
(PDB code: 1TOX) nor EB-47 made any specific interactions with the D-loop 
and region was not resolved in the electron density in the NAD+ bound diphtheria 
toxin crystal structure. The substrate could have any of the mentioned 
interactions made by EB-47 with TNKS2 or NAD+ in diphtheria toxin.  
Compound 10 is not the actual substrate and has differences in the chemical 
structure compared to NAD+, as it does not contain the diphosphate and ribose 
parts of substrate. This could cause changes also in the binding of nicotinamide 
and adenosine mimicking moieties. However, from the comparison of complex 
crystal structures of TNKS2-10 and previously reported diphtheria toxin-NAD+, 
it is evident that catalytic glutamate of TNKS2 would be close enough (~ 2.9 Å) 
to NAD+ ribose, missing in compound 10. It would stabilize the the 
oxacarbenium ion transition state through electrostatic interaction, required for 
catalysis of NAD+ (Kleine et al, 2008). The crystal structures in complex with 
nicotinamide and EB-47, as well as comparisons with diphtheria toxin structure 
forms our current view of the substrate and byproduct binding to tankyrases.  The 
mechanism of ADP-ribose transfer in tankyrases and other ARTDs requires more 
research and structures in complex with NAD+ and an acceptor molecule would 
give an insight on the molecular details of the reaction.   
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6 Conclusions and future perspectives 
Tankyrases are implicated in many cellular processes and are emerging as 
potential drug targets. Therefore, there has been growing interest towards 
discovering and designing new inhibitors against them. This thesis work was also 
focused on discovering selective and potent tankyrase inhibitors, as there were no 
specific tankyrase inhibitors available before this project was started.  
Important conclusions drawn from this study are: 
1. Fluorescence-based activity assay developed during this study is suitable 
for screening the chemical libraries and to measure the IC50-values. Good 
Z´-value, simplicity, feasibility, low cost, high DMSO tolerance also 
made this homogeneous activity assay suitable for high throughput 
screening of compounds. Activity assay described for TNKS1 is 
optimized for TNKS2 catalytic domain and calculations of assay 
parameters confirmed its suitability for screening.  
2. Flavones bind to nicotinamide binding site in the NAD+ binding groove. 
However, they are missing the amide present in other inhibitors binding 
to nicotinamide binding site. They are the most potent inhibitors of 
tankyrases among different classes of flavonoids.  
3. It is possible to create potent tankyrase inhibitors utilizing the flavone 
scaffold. Para position of the phenyl ring is best to introduce 
substitutions in order to increase the potency. Substitutions at other sites 
do not increase the potency or cause loss of activity. Hydrophobic 
substitutions at 4´-position increase the selectivity toward tankyrases. 
Despite the conserved binding site, hit compounds showed nanomolar 
potency and isoenzyme selectivity for tankyrases and efficiently 
inhibited the Wnt signaling in a cell-based assay. 
4. IWR-1 was the first compound that was shown to bind to adenosine site 
in the binding motif. Co-crystal structure of TNKS2 with IWR-1 showed 
that compound utilized the flexibility of the D-loop to bind to the NAD+ 
binding groove. 
5. Co-crystal structure of TNKS 2 with EB-47 (NAD+ mimic compound) 
allowed to analyze the substrate binding mode. Soaking NAD+ to 
TNKS2 crystals led to nicotinamide-bound complex that showed the 
interactions made by nicotinamide with protein molecule.  
6. Evaluation of known small molecule inhibitors of ARTD1 against 
tankyrases showed that some of the compounds are also potent tankyrase 
inhibitors. This could affect the studies done with these compounds 
including the outcomes of clinical trials with ARTD1 inhibitors.  
In general, inhibitor discovery in the ARTD field has mostly been focused on 
nicotinamide site. However, after TNKS2-IWR-1 complex structure, IWR-1 
scaffold has also been optimized and potency has been improved from 130 nM to 
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1 nM using molecular modeling and structure-based drug design (Bregman et al, 
2013a). The potency measurements and analysis of crystal structures have shown 
that tankyrase inhibitors binding to adenosine site are in general more selective 
towards tankyrases in comparison to compounds binding to the nicotinamide site 
(Haikarainen et al, 2013b; Shultz et al, 2012; Voronkov et al, 2013). There have 
also been efforts to develop dual binders that bind to both sites of the NAD+ 
binding cleft (Bregman et al, 2013b; Shultz et al, 2013a).  
Recently, it was shown that colorectal tumor growth developed by the mutation 
in APC gene could be suppressed by small-molecule tankyrase inhibitors G007-
LK and G244-LM (Lau et al, 2013). Tankyrase inhibition led to the inhibition of 
Wnt signaling and consequently destabilization of β-catenin. However, this also 
affected cell proliferation and caused toxicity in the intestinal gland, a probable 
on-target effect, which has raised questions on utilization of tankyrase inhibitors 
in cancer therapy. In future, these questions should be addressed and research 
should be done to clearly define the role of tankyrase in cancer or other diseases.  
In summary, inhibitors binding to the nicotinamide site were discovered and 
selective nature of an adenosine site binding inhibitor was studied. The 
biochemical assay will be useful for in vitro screening of compounds and 
extensive crystallographic work conducted in this thesis will hopefully facilitate 
further development of tankyrase inhibitors.  
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